0001438133-22-000021 | 10-K | XBRL Viewer

Print Document View Excel Document

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) $ in Thousands	Dec. 31, 2020 USD ($)
Statement of Cash Flows [Abstract]
Unamortized debt issuance costs	$ 8,809

Income Taxes - Schedule of Components of Income Tax (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Current:
Federal	$ 0	$ 0	$ 0
State	174	75	86
Foreign	161	151	88
Total current tax expense	335	226	174
Deferred:
Federal	0	(1,760)	(21)
State	0	(366)	(4)
Foreign	0	0	0
Total deferred income tax benefit	0	(2,126)	(25)
Income tax expense (benefit)	$ 335	$ (1,900)	$ 149

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Operating Activities
Net income (loss)	$ 15,566	$ (34,382)	$ (24,753)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization expense	13,845	10,451	6,072
Amortization of debt discount and issuance costs	1,727	10,096	0
Provision for expected credit losses	2,333	3,016	2,322
Provision (recovery) for inventory obsolescence	467	(57)	2,353
Change in fair value of common stock warrants	1,386	17,087	11,075
Amortization of premium (discount) on short-term investments	365	(1,296)	(565)
Benefit for deferred income taxes	0	(2,126)	(25)
Stock-based compensation expense	60,752	58,431	58,071
Other	546	38	(295)
Changes in operating assets and liabilities:
Accounts receivable, net	(30,980)	(38,837)	(13,698)
Inventories	(4,954)	(15,361)	(30,975)
Prepaid and other current assets	(1,570)	(2,427)	(584)
Other long-term assets	1,313	129	(580)
Accounts payable	10,275	1,118	8,910
Accrued expenses	4,640	(3,256)	4,076
Employee-related liabilities	17,399	5,339	4,285
Deferred revenue	10,611	7,029	4,589
Operating leases and other current liabilities	6,217	5,789	4,216
Other long-term liabilities	1,421	3,888	7,412
Net cash provided by operating activities	111,359	24,669	41,906
Investing Activities
Purchases of short-term investments	(733,388)	(497,076)	(164,572)
Proceeds from maturities of short-term investments	545,735	180,922	114,908
Proceeds from sales of short-term investments	24,288	52,392	12,250
Purchases of property and equipment	(14,180)	(27,408)	(19,541)
Acquisition of intangible assets and equity investments	(9,331)	(4,886)	0
Net cash used in investing activities	(186,876)	(296,056)	(56,955)
Financing Activities
Proceeds from issuance of convertible senior notes, net of $8,809 debt issuance costs	0	278,691	0
Payment for capped call transactions related to convertible senior notes	0	(34,069)	0
Proceeds from issuance of common stock under Company stock plans, net	51,340	66,866	23,880
Proceeds from exercise of common stock warrants	592	2,950	327
Net cash provided by financing activities	51,932	314,438	24,207
Effect of foreign exchange rate changes on cash	153	387	191
Net increase (decrease) in cash and cash equivalents	(23,432)	43,438	9,349
Cash and cash equivalents at beginning of period	94,613	51,175	41,826
Cash and cash equivalents at end of period	71,181	94,613	51,175
Supplemental disclosures of cash flow information
Interest paid	4,313	2,707	0
Income taxes paid	260	177	67
Supplemental schedule of non-cash investing and financing activities
Right-of-use assets obtained in exchange for operating lease obligations	15,191	11,022	11,635
Property and equipment included in accounts payable	1,034	1,082	2,134
Intangible costs in accounts payable and other long-term liabilities	$ 1,029	$ 2,244	$ 0

Leases (Tables)

12 Months Ended

Dec. 31, 2021

Leases [Abstract]

Schedule of Lease Cost

The Company’s lease costs recorded in the consolidated statements of operations were as follows (in thousands):


	Year Ended December 31,
	2021		2020		2019
Operating lease cost	$	8,627	$	7,514	$	4,542
Short-term lease cost	90		219		165
Total lease cost	$	8,717	$	7,733	$	4,707

The weighted-average remaining lease term and weighted-average discount rate for operating leases were as follows:


	December 31, 2021		December 31, 2020
Weighted-average remaining lease term (in years)	5.0		3.7
Weighted-average discount rate used to determine operating lease liabilities	5.6	%	5.9	%

Schedule of Future Minimum Payments Under Non-cancellable Operating Leases

Maturities of operating lease liabilities at December 31, 2021 were as follows (in thousands):


Years Ending December 31,
2022	$	9,281
2023	6,949
2024	5,744
2025	5,825
2026	5,531
Thereafter	5,144
Total undiscounted lease payments	38,474
Less: amount representing interest	(5,273)
Present value of operating lease liabilities	33,201
Less: current portion of operating lease liabilities	(9,279)
Operating lease liabilities - long-term	$	23,922

Future minimum payments for monthly base rent due under the respective High Bluff Lease and Tech Center Lease terms, are currently estimated to be as follows (in thousands), subject to a number of factors, including the actual Commencement Date of the lease:


Years Ending December 31,	High Bluff Lease(1)		Tech Center Lease(2)		Total
2022	$	1,029	$	—	$	1,029
2023	1,594		6,453		8,047
2024	403		11,313		11,716
2025	—		12,694		12,694
2026	—		15,181		15,181
2027 through 2035	—		145,583		145,583
Total	$	3,026	$	191,224	$	194,250

(1) The Company currently estimates that the Commencement Date will occur in the second quarter of 2022, at which time the operating lease right-of-use assets and liabilities will be recorded.

(2) The Company currently estimates that the Phase I Commencement Date will occur in the first quarter of 2022, and the Phase II Commencement Date will occur in the first quarter of 2025, at which time the respective operating lease right-of-use assets and liabilities will be recorded.

Fair Value Measurements - Summary of Changes in Fair Value of Total Level 3 Financial Assets (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance at beginning of year	$ 14,261	$ 23,509
Loss recognized from the change in fair value of common stock warrants	1,386	17,087
Common stock warrants exercised during the period	(15,500)	(26,335)
Balance at end of year	$ 147	$ 14,261

Income Taxes - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Line Items]
Less valuation allowance	$ 146,423,000	$ 121,627,000
Unrecognized tax benefits	11,800,000
Accrual interest and penalties	$ 0	$ 0
Minimum
Income Tax Disclosure [Line Items]
Income tax realization	50.00%
California
Income Tax Disclosure [Line Items]
NOL carryforwards subject to expiration	$ 171,800,000
Federal
Income Tax Disclosure [Line Items]
NOL carry forwards amount	301,200,000
NOL carryforwards not subject to expiration	112,100,000
NOL carryforwards subject to expiration	189,100,000
Federal \| Research Tax Credit Carryforward
Income Tax Disclosure [Line Items]
Tax credit carryforward, amount	12,900,000
State and Local
Income Tax Disclosure [Line Items]
NOL carry forwards amount	291,000,000.0
California \| Research Tax Credit Carryforward
Income Tax Disclosure [Line Items]
Tax credit carryforward, amount	$ 15,500,000

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2021

Income Tax Disclosure [Abstract]

Schedule of Loss Before Provision for Income Taxes

The income (loss) before provision for income taxes for the Company’s domestic and international operations was as follows (in thousands):


	Year Ended December 31,
	2021		2020		2019
U.S.	$	15,211	$	(36,667)	$	(24,888)
Foreign	690		385		284
Income (loss) before provision for income taxes	$	15,901	$	(36,282)	$	(24,604)

Schedule of Components of Income Tax Expense (Benefit)

The components of income tax expense (benefit) were as follows (in thousands):


	Year Ended December 31,
	2021		2020		2019
Current:
Federal	$	—	$	—	$	—
State	174		75		86
Foreign	161		151		88
Total current tax expense	335		226		174
Deferred:
Federal	—		(1,760)		(21)
State	—		(366)		(4)
Foreign	—		—		—
Total deferred income tax benefit	—		(2,126)		(25)
Income tax expense (benefit)	$	335	$	(1,900)	$	149

Schedule of Effective Income Tax Rate Reconciliation

The expense (benefit) for income taxes reconciles to the amount computed by applying the federal statutory rate to loss before taxes as follows (in thousands):


	Year Ended December 31,
	2021		2020		2019
Income tax expense (benefit) at federal statutory rate (1)	$	3,339	$	(7,619)	$	(5,167)
State income tax, net of federal benefit	(254)		(2,792)		(1,174)
Warrants revaluation	356		3,588		2,326
Research and development credits	(5,703)		(5,330)		(2,091)
Section 382 limitation	(97)		1,021		25,043
Stock-based compensation	(7,609)		(18,309)		(8,974)
Officers' compensation	4,024		2,612		3,133
Other	124		479		972
Change in valuation allowance	6,155		24,450		(13,919)
Income tax expense (benefit)	$	335	$	(1,900)	$	149

(1)For the years ended December 31, 2021, 2020 and 2019, the federal statutory tax rate was 21%.

Schedule of Deferred Tax Assets and Liabilities


	December 31,
	2021		2020
Deferred tax assets:
Net operating loss (NOL) carryforwards	$	78,961	$	86,898
Research and development tax credits carryforwards	16,761		11,261
Capitalized research and development expenses	5,135		6,840
Accrued compensation	28,970		24,038
Lease liabilities	8,012		6,112
Other	20,608		12,096
Total deferred tax assets	158,447		147,245
Deferred tax liabilities:
Convertible senior notes	—		(11,224)
Fixed assets	(3,847)		(7,675)
Other	(8,177)		(6,719)
Total deferred tax liabilities	(12,024)		(25,618)
Less valuation allowance	(146,423)		(121,627)
Net deferred tax assets	$	—	$	—

Schedule of Unrecognized Tax Benefits

The following table summarizes the activity related to the Company’s gross unrecognized tax benefits at the beginning and end of the years ended December 31, 2021, 2020 and 2019 (in thousands):


	Year Ended December 31,
	2021		2020		2019
Gross unrecognized tax benefits at the beginning of the year	10,107		$	6,580	$	8,824
Increases related to current year positions	3,482		2,234		1,076
Increases (decreases) related to prior year positions	—		1,293		(3,320)
Gross unrecognized tax benefits at the end of the year	$	13,589	$	10,107	$	6,580

Short-Term Investments - Summary of Contractual Maturities of Available-For-Sale Debt Securities (Details) $ in Thousands	Dec. 31, 2021 USD ($)
Cash Cash Equivalents And Short Term Investments [Line Items]
Within One Year	$ 417,733
One to Two Years	134,897
Estimated Fair Value	552,630
U.S. Treasury securities
Cash Cash Equivalents And Short Term Investments [Line Items]
Within One Year	105,231
One to Two Years	116,493
Estimated Fair Value	221,724
Commercial paper
Cash Cash Equivalents And Short Term Investments [Line Items]
Within One Year	218,381
One to Two Years	0
Estimated Fair Value	218,381
Corporate debt securities
Cash Cash Equivalents And Short Term Investments [Line Items]
Within One Year	58,836
One to Two Years	0
Estimated Fair Value	58,836
U.S. Government-sponsored enterprises
Cash Cash Equivalents And Short Term Investments [Line Items]
Within One Year	32,282
One to Two Years	18,404
Estimated Fair Value	50,686
Supranational bonds
Cash Cash Equivalents And Short Term Investments [Line Items]
Within One Year	3,003
One to Two Years	0
Estimated Fair Value	$ 3,003

Income Taxes - Loss Before Provision for Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
U.S.	$ 15,211	$ (36,667)	$ (24,888)
Foreign	690	385	284
Income (loss) before income taxes	$ 15,901	$ (36,282)	$ (24,604)

- Definition

Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 940
-SubTopic 20
-Section 25
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(10))
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(8))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(15))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

+ Details

Fourth Quarter Financial Data (Unaudited) (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Quarterly Financial Information Disclosure [Abstract]
Sales	$ 209,996	$ 168,065	$ 702,799	$ 498,830	$ 362,305
Gross profit	113,729	90,556	376,215	260,520	194,212
Operating expenses	100,991	71,894	353,562	268,477	210,934
Operating income	12,738	18,662	22,653	(7,957)	(16,722)
Net income	$ 10,808	$ 17,000	$ 15,566	$ (34,382)	$ (24,753)
Basic net income per share (in dollars per share)	$ 0.17	$ 0.27	$ 0.25	$ (0.56)	$ (0.42)
Diluted net income per share (in dollars per share)	$ 0.16	$ 0.22	$ 0.24	$ (0.56)	$ (0.42)

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

+ Details

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

+ Details

- Definition

Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1,2)
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

+ Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580

Reference 25: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

+ Details

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

+ Details

Composition of Certain Financial Statement Items (Tables)

12 Months Ended

Dec. 31, 2021

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Schedule of Accounts Receivable

Accounts receivable, net consisted of the following at (in thousands):


	December 31,
	2021		2020
Accounts receivable	$	114,974	$	86,052
Less: allowance for credit losses	(4,249)		(3,857)
Accounts receivable, net	$	110,725	$	82,195

Schedule of Reconciliation of Change in Estimated Allowance for Doubtful Accounts

The following table provides a reconciliation of the changes in the allowance for estimated accounts receivable credit losses for the years ended December 31, 2021, 2020 and 2019 (in thousands):


	Year Ended December 31,
	2021		2020		2019
Balance at beginning of the year	$	3,857	$	3,304	$	1,837
Provision for expected credit losses	2,333		3,016		2,322
Write-offs and adjustments, net of recoveries	(1,941)		(2,463)		(855)
Balance at end of the year	$	4,249	$	3,857	$	3,304

Schedule of Inventory

Inventories consisted of the following at (in thousands):


	December 31,
	2021		2020
Raw materials	$	26,911	$	30,880
Work-in-process	16,612		15,664
Finished goods	25,028		17,177
Total inventories	$	68,551	$	63,721

Schedule of Property and Equipment

Property and equipment, net consisted of the following at (in thousands):


	December 31,
	2021		2020
Leasehold improvements	$	25,245	$	22,834
Office furniture and equipment	9,943		9,876
Computer equipment and software	11,544		12,219
Manufacturing and scientific equipment	52,823		44,026
Total cost	99,555		88,955
Less: accumulated depreciation and amortization	(49,169)		(38,933)
Total property and equipment, net	$	50,386	$	50,022

Schedule of Capitalized Patents

Intangible assets subject to amortization consist of technology-based intangibles related to the Company’s acquisition of Sugarmate, as well as patents purchased or licensed that are related to the Company’s commercialized products. Intangible assets at December 31, 2021 and 2020, which were included in other long-term assets on the consolidated balance sheets, were as follows (in thousands):


	December 31,
	2021		2020
Intangible assets, gross amount	$	12,502	$	12,502
Accumulated amortization	(5,866)		(3,697)
Intangible assets, net	$	6,636	$	8,805
Weighted average remaining amortization period (in months)	41		52

Summary of Significant Accounting Policies - Schedule of Anti-Dilutive Securities (Detail) - shares shares in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount (in shares)	5,679	7,086	6,235
Options to purchase common stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount (in shares)	3,124	5,021	5,619
Unvested restricted stock units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount (in shares)	0	78
Warrants to purchase common stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount (in shares)	1	379	611
Awards to be granted under the ESPP
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount (in shares)	0	3	5
Convertible senior notes (if-converted)
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount (in shares)	2,554	1,605

Summary of Significant Accounting Policies - Deferred Revenue Related to Performance Obligations (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Disaggregation of Revenue [Line Items]
Deferred revenue	$ 10,182	$ 6,082
Transferred over Time
Disaggregation of Revenue [Line Items]
Deferred revenue	9,625	5,508
Other long-term liabilities	16,940	10,426
Total	$ 26,565	$ 15,934

Short-Term Investments

12 Months Ended

Dec. 31, 2021

Investments, Debt and Equity Securities [Abstract]

Short-Term Investments

The Company invests in marketable securities primarily consisting of debt instruments of the U.S. Government, U.S. Government-sponsored enterprises, and financial institutions and corporations with strong credit ratings. The following represents a summary of the estimated fair value of short-term investments at December 31, 2021 and 2020 (in thousands):


At December 31, 2021	Amortized Cost		Gross Unrealized Gain		Gross Unrealized Loss		Estimated Fair Value
Available-for-sale securities:
U.S. Treasury securities	$	222,206	$	—	$	(482)	$	221,724
Commercial paper	218,391		14		(24)		218,381
Corporate debt securities	58,881		—		(45)		58,836
U.S. Government-sponsored enterprises	50,773		1		(88)		50,686
Supranational bonds	3,003		—		—		3,003
Total	$	553,254	$	15	$	(639)	$	552,630


At December 31, 2020	Amortized Cost		Gross Unrealized Gain		Gross Unrealized Loss		Estimated Fair Value
Available-for-sale securities:
U.S. Treasury securities	$	143,244	$	12	$	(2)	$	143,254
Commercial paper	108,892		5		(1)		108,896
Corporate debt securities	85,788		48		(13)		85,823
U.S. Government-sponsored enterprises	52,330		21		(1)		52,350
Total	$	390,254	$	86	$	(17)	$	390,323

The contractual maturities of available-for-sale debt securities as of December 31, 2021, were as follows (in thousands):


	Years to Maturity
At December 31, 2021	Within One Year		One to Two Years		Estimated Fair Value
U.S. Treasury securities	$	105,231	$	116,493	$	221,724
Commercial paper	218,381		—		218,381
Corporate debt securities	58,836		—		58,836
U.S. Government-sponsored enterprises	32,282		18,404		50,686
Supranational bonds	3,003		—		3,003
Total	$	417,733	$	134,897	$	552,630

The Company has classified all marketable securities, regardless of maturity, as short-term investments based upon the Company’s ability and intent to use any of those marketable securities to satisfy the Company’s liquidity requirements.

The Company reviews the portfolio of available-for-sale debt securities quarterly to determine if any investment is impaired due to changes in credit risk or other potential valuation concerns. Unrealized losses on available-for-sale debt securities at December 31, 2021 were not significant and were primarily due to changes in market interest rates. The Company does not intend to sell the available-for-sale debt securities that are in an unrealized loss position, and it is not more likely than not that the Company will be required to sell these debt securities before recovery of their amortized cost bases, which may be at maturity. Based on the credit quality of the available-for-sale debt securities in an unrealized loss position, and the Company’s estimates of future cash flows to be collected from those securities, the Company believes the unrealized losses are not credit losses. Accordingly, the Company did not recognize any impairment losses related to its available-for-sale debt securities at December 31, 2021.

Fair Value Measurements - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt securities, available for sale	$ 552,630	$ 390,323
Maximum
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash equivalents maturity term	3 months
U.S. Treasury securities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt securities, available for sale	$ 221,724	143,254
Commercial paper
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt securities, available for sale	218,381	108,896
Corporate debt securities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt securities, available for sale	58,836	85,823
Supranational bonds
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt securities, available for sale	3,003
Fair Value, Measurements, Recurring
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total assets	600,916	477,623
Common stock warrants	147	14,261
Total liabilities	147	14,261
Fair Value, Measurements, Recurring \| Cash equivalents
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash equivalents	48,286	87,300
Fair Value, Measurements, Recurring \| U.S. Treasury securities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt securities, available for sale	221,724	143,254
Fair Value, Measurements, Recurring \| Commercial paper
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash equivalents	218,381	108,896
Fair Value, Measurements, Recurring \| U.S. Government-sponsored enterprises
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt securities, available for sale	50,686	52,350
Fair Value, Measurements, Recurring \| Corporate debt securities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt securities, available for sale	58,836	85,823
Fair Value, Measurements, Recurring \| Supranational bonds
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt securities, available for sale	3,003
Fair Value, Measurements, Recurring \| Level 1
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total assets	270,010	230,554
Common stock warrants	0	0
Total liabilities	0	0
Fair Value, Measurements, Recurring \| Level 1 \| Cash equivalents
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash equivalents	48,286	87,300
Fair Value, Measurements, Recurring \| Level 1 \| U.S. Treasury securities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt securities, available for sale	221,724	143,254
Fair Value, Measurements, Recurring \| Level 1 \| Commercial paper
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash equivalents	0	0
Fair Value, Measurements, Recurring \| Level 1 \| U.S. Government-sponsored enterprises
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt securities, available for sale	0	0
Fair Value, Measurements, Recurring \| Level 1 \| Corporate debt securities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt securities, available for sale	0	0
Fair Value, Measurements, Recurring \| Level 1 \| Supranational bonds
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt securities, available for sale	0
Fair Value, Measurements, Recurring \| Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total assets	330,906	247,069
Common stock warrants	0	0
Total liabilities	0	0
Fair Value, Measurements, Recurring \| Level 2 \| Cash equivalents
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash equivalents	0	0
Fair Value, Measurements, Recurring \| Level 2 \| U.S. Treasury securities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt securities, available for sale	0	0
Fair Value, Measurements, Recurring \| Level 2 \| Commercial paper
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash equivalents	218,381	108,896
Fair Value, Measurements, Recurring \| Level 2 \| U.S. Government-sponsored enterprises
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt securities, available for sale	50,686	52,350
Fair Value, Measurements, Recurring \| Level 2 \| Corporate debt securities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt securities, available for sale	58,836	85,823
Fair Value, Measurements, Recurring \| Level 2 \| Supranational bonds
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt securities, available for sale	3,003
Fair Value, Measurements, Recurring \| Level 3
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total assets	0	0
Common stock warrants	147	14,261
Total liabilities	147	14,261
Fair Value, Measurements, Recurring \| Level 3 \| Cash equivalents
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash equivalents	0	0
Fair Value, Measurements, Recurring \| Level 3 \| U.S. Treasury securities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt securities, available for sale	0	0
Fair Value, Measurements, Recurring \| Level 3 \| Commercial paper
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash equivalents	0	0
Fair Value, Measurements, Recurring \| Level 3 \| U.S. Government-sponsored enterprises
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt securities, available for sale	0	0
Fair Value, Measurements, Recurring \| Level 3 \| Corporate debt securities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt securities, available for sale	0	$ 0
Fair Value, Measurements, Recurring \| Level 3 \| Supranational bonds
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt securities, available for sale	$ 0

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)
$ in Thousands

Total

Cumulative Effect, Period of Adoption, Adjustment

^[1]

Common Stock

Additional Paid-in Capital

Cumulative Effect, Period of Adoption, Adjustment

^[1]

Accumulated Other Comprehensive Income (Loss)

Accumulated Deficit

Cumulative Effect, Period of Adoption, Adjustment

^[1]

Beginning balance (in shares) at Dec. 31, 2018

57,554,000

Beginning balance at Dec. 31, 2018

$ 131,275

$ 57

$ 731,306

$ (13)

$ (600,075)

Increase (Decrease) in Stockholders' Equity

Exercise of stock options (in shares)

1,422,000

Exercise of stock options

17,675

$ 1

17,674

Issuance of common stock for Employee Stock Purchase Plan (in shares)

327,000

Issuance of common stock for Employee Stock Purchase Plan

6,206

$ 1

6,205

Exercise of common stock warrants (in shares)

93,000

Exercise of common stock warrants

327

$ 0

327

Fair value of common stock warrants at time of exercise

5,492

Stock-based compensation expense

58,622

Unrealized gain (loss) on short-term investments, net of deferred tax

Foreign currency translation adjustments

Net income

(24,753)

Ending balance (in shares) at Dec. 31, 2019

59,396,000

Ending Balance at Dec. 31, 2019

$ 194,979

$ 59

819,626

122

(624,828)

Increase (Decrease) in Stockholders' Equity

Exercise of stock options (in shares)

2,339,467

2,341,000

Exercise of stock options

$ 57,750

$ 2

57,748

Issuance of common stock for Employee Stock Purchase Plan (in shares)

303,000

Issuance of common stock for Employee Stock Purchase Plan

9,116

$ 1

9,115

Exercise of common stock warrants (in shares)

295,000

Exercise of common stock warrants

2,950

Fair value of common stock warrants at time of exercise

26,335

Equity component of convertible senior notes issuance, net of issuance costs

85,803

Payment for capped call transactions related to convertible senior notes

(34,069)

Stock-based compensation expense

57,725

Unrealized gain (loss) on short-term investments, net of deferred tax

(20)

Foreign currency translation adjustments

118

Net income

(34,382)

Ending balance (in shares) at Dec. 31, 2020

62,335,000

Ending Balance at Dec. 31, 2020

$ 366,305

$ (76,754)

$ 62

1,025,233

$ (85,803)

220

(659,210)

$ 9,049

Increase (Decrease) in Stockholders' Equity

Accounting Standards Update [Extensible List]

Accounting Standards Update 2020-06

Exercise of stock options (in shares)

1,128,791

1,129,000

Exercise of stock options

$ 41,823

$ 2

41,821

Vesting of restricted stock units, net of shares withheld for taxes (in shares)

38,000

Vesting of restricted stock units, net of shares withheld for taxes

(1,551)

Issuance of common stock for Employee Stock Purchase Plan (in shares)

173,000

Issuance of common stock for Employee Stock Purchase Plan

11,069

Exercise of common stock warrants (in shares)

158,000

Exercise of common stock warrants

899

Fair value of common stock warrants at time of exercise

15,500

Stock-based compensation expense

61,091

Unrealized gain (loss) on short-term investments, net of deferred tax

(693)

Foreign currency translation adjustments

(143)

Net income

15,566

Ending balance (in shares) at Dec. 31, 2021

63,833,000

Ending Balance at Dec. 31, 2021

$ 433,112

$ 64

$ 1,068,259

$ (616)

$ (634,595)

[1]	The Company adopted ASU No. 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity effective January 1, 2021 (see Note 2, “Summary of Significant Accounting Policies”).

Summary of Significant Accounting Policies - Summary of Customers Accounted for 10% or More (Detail) - Customer Concentration Risk	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Accounts Receivable \| Customer A
Concentration Risk [Line Items]
Customers accounted for 10% or more		12.70%
Accounts Receivable \| Customer B
Concentration Risk [Line Items]
Customers accounted for 10% or more	11.20%	12.30%
Sales Revenue, Net \| Customer B
Concentration Risk [Line Items]
Customers accounted for 10% or more	11.90%	15.90%	14.80%
Sales Revenue, Net \| Customer C
Concentration Risk [Line Items]
Customers accounted for 10% or more		12.90%	15.40%

Debt - Convertible Senior Notes Additional Information (Detail)	1 Months Ended	12 Months Ended
	May 31, 2020 USD ($) segment trading_day $ / shares	Dec. 31, 2021 USD ($) $ / shares	Dec. 31, 2020 USD ($)	Jan. 01, 2021 USD ($)	May 12, 2020 $ / shares
Debt Instrument [Line Items]
Accumulated deficit		$ (634,595,000)	$ (659,210,000)
Convertible senior notes, net - long-term		281,467,000	202,984,000
Unamortized debt issuance costs			8,809,000
Capped call transactions net cost			34,069,000
Cumulative Effect, Period of Adoption, Adjustment \| Accounting Standards Update 2020-06
Debt Instrument [Line Items]
Accumulated deficit				$ 9,000,000
Additional paid in capital				(85,800,000)
Convertible senior notes, net - long-term				$ 76,800,000
Convertible senior notes \| Convertible senior notes
Debt Instrument [Line Items]
Principal	$ 287,500,000	287,500,000	287,500,000
Interest rate	1.50%
Net proceeds from issuance of convertible notes	$ 244,600,000
Debt instrument, convertible, conversion ratio	0.0088836
Conversion price (in dollars per share) \| $ / shares	$ 112.57
Principal amount		$ 96,900,000
Debt instrument, convertible, threshold trading days \| segment	20
Debt instrument, convertible, threshold trading days consecutive trading days \| trading_day	30
Redemption price percentage	100.00%
Carrying amount of the equity component	$ 88,500,000		85,803,000
Effective interest rate	9.90%	2.20%
Debt issuance costs related to equity component	$ 2,700,000
Debt issuance costs related to liability component	6,100,000
Unamortized debt issuance costs		$ 6,033,000	$ 5,446,000
Remaining debt term		3 years 3 months 18 days
Capped call transactions net cost	$ 34,100,000
Debt instrument, initial cap price per share (in dollars per share) \| $ / shares	$ 173.18
Stock price per share (in dollars per share) \| $ / shares					$ 86.59
Convertible senior notes \| Convertible senior notes \| Conversion Instance, 130%
Debt Instrument [Line Items]
Debt instrument, convertible, threshold trading days \| trading_day	20
Debt instrument, convertible, threshold trading days consecutive trading days \| trading_day	30
Convertible senior notes \| Convertible senior notes \| Conversion Instance, 98%
Debt Instrument [Line Items]
Debt instrument, convertible, threshold trading days \| trading_day	5
Debt instrument, convertible, threshold trading days consecutive trading days \| trading_day	5
Convertible senior notes \| Convertible senior notes \| Minimum
Debt Instrument [Line Items]
Conversion price (in dollars per share) \| $ / shares	$ 112.57	$ 112.57
Debt instrument, convertible, threshold percentage of stock price trigger	130.00%
Convertible senior notes \| Convertible senior notes \| Minimum \| Conversion Instance, 130%
Debt Instrument [Line Items]
Debt instrument, convertible, threshold percentage of stock price trigger	130.00%
Convertible senior notes \| Convertible senior notes \| Minimum \| Conversion Instance, 98%
Debt Instrument [Line Items]
Debt instrument, convertible, threshold percentage of stock price trigger	98.00%
Convertible senior notes \| Convertible senior notes \| Maximum
Debt Instrument [Line Items]
Conversion price (in dollars per share) \| $ / shares	$ 173.18

Debt (Tables)

12 Months Ended

Dec. 31, 2021

Debt Disclosure [Abstract]

Schedule of Convertible Notes

The liability and equity components of the Notes consisted of the following (in thousands):


	December 31, 2021		December 31, 2020
Liability:
Principal amount	$	287,500	$	287,500
Unamortized debt issuance costs	(6,033)		(5,446)
Unamortized debt discount	—		$	(79,070)
Net carrying amount	$	281,467	$	202,984
Carrying amount of the equity component	$	—	$	85,803

Schedule of Interest Expense Recognized

The following table details interest expense recognized related to the Notes for the years ended December 31, 2021 and 2020 (in thousands):



	December 31, 2021		December 31, 2020
Contractual interest expense	$	4,313	$	2,707
Amortization of debt issuance costs	1,727		652
Amortization of debt discount	N/A		9,446
Total interest expense	$	6,040	$	12,805

Short-Term Investments (Tables)

12 Months Ended

Dec. 31, 2021

Investments, Debt and Equity Securities [Abstract]

Schedule of Estimated Fair Value of Short-Term Investments

The following represents a summary of the estimated fair value of short-term investments at December 31, 2021 and 2020 (in thousands):


At December 31, 2021	Amortized Cost		Gross Unrealized Gain		Gross Unrealized Loss		Estimated Fair Value
Available-for-sale securities:
U.S. Treasury securities	$	222,206	$	—	$	(482)	$	221,724
Commercial paper	218,391		14		(24)		218,381
Corporate debt securities	58,881		—		(45)		58,836
U.S. Government-sponsored enterprises	50,773		1		(88)		50,686
Supranational bonds	3,003		—		—		3,003
Total	$	553,254	$	15	$	(639)	$	552,630


At December 31, 2020	Amortized Cost		Gross Unrealized Gain		Gross Unrealized Loss		Estimated Fair Value
Available-for-sale securities:
U.S. Treasury securities	$	143,244	$	12	$	(2)	$	143,254
Commercial paper	108,892		5		(1)		108,896
Corporate debt securities	85,788		48		(13)		85,823
U.S. Government-sponsored enterprises	52,330		21		(1)		52,350
Total	$	390,254	$	86	$	(17)	$	390,323

Schedule of Contractual Maturities of Available - For- Sale Debt Securities

The contractual maturities of available-for-sale debt securities as of December 31, 2021, were as follows (in thousands):


	Years to Maturity
At December 31, 2021	Within One Year		One to Two Years		Estimated Fair Value
U.S. Treasury securities	$	105,231	$	116,493	$	221,724
Commercial paper	218,381		—		218,381
Corporate debt securities	58,836		—		58,836
U.S. Government-sponsored enterprises	32,282		18,404		50,686
Supranational bonds	3,003		—		3,003
Total	$	417,733	$	134,897	$	552,630

Composition of Certain Financial Statement Items - Summary of Property and Equipment (Detail) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Total cost	$ 99,555	$ 88,955
Less: accumulated depreciation and amortization	(49,169)	(38,933)
Total property and equipment, net	50,386	50,022
Leasehold improvements
Property, Plant and Equipment [Line Items]
Total cost	25,245	22,834
Office furniture and equipment
Property, Plant and Equipment [Line Items]
Total cost	9,943	9,876
Computer equipment and software
Property, Plant and Equipment [Line Items]
Total cost	11,544	12,219
Manufacturing and scientific equipment
Property, Plant and Equipment [Line Items]
Total cost	$ 52,823	$ 44,026

Summary of Significant Accounting Policies - Numerator and Denominator of the Basic and Diluted Net Income Per Share Computations (Details) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Net income - basic			$ 15,566
Net income - diluted	$ 10,840	$ 14,181	$ 15,566
Weighted average shares outstanding - basic (in shares)	63,650	62,249	63,000	60,990	58,507
Dilutive common shares equivalents - Warrants to purchase common stock (in shares)			157
Weighted average shares outstanding - diluted (in shares)	65,927	65,678	64,349	60,990	58,507
Options to purchase common stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Dilutive common stock equivalents - Incremental common shares attributable to dilutive effect (in shares)			1,129
Unvested restricted stock units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Dilutive common stock equivalents - Incremental common shares attributable to dilutive effect (in shares)			62
Awards to be granted under the ESPP
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Dilutive common stock equivalents - Incremental common shares attributable to dilutive effect (in shares)			1

Business Segment and Geographic Information

12 Months Ended

Dec. 31, 2021

Segment Reporting [Abstract]

Business Segment and Geographic Information

Segment Reporting

Operating segments are identified as components of an enterprise about which discrete financial information is available for evaluation by the chief operating decision-maker (CODM) in making decisions regarding resource allocation and assessing performance. The Company is organized based on its current product portfolio, which consists primarily of insulin pumps, disposable insulin cartridges and infusion sets for the storage and delivery of insulin. The Company views its operations and manages its business as one segment and a single reporting unit because key operating decisions and resource allocations are made by the CODM using consolidated financial data.

Disaggregation of Revenue

The Company primarily sells its products through national and regional distributors in the United States on a non-exclusive basis, and through distribution partners outside the United States, including in select European countries, Canada, Australia, New Zealand, Saudi Arabia and South Africa. In the United States and Canada, the Company utilizes a direct sales force. The Company disaggregates its revenue by geography and by major sales channel as management believes these categories best depict how the nature, amount and timing of revenues and cash flows are affected by economic factors.

Revenues by Geographic Region and Customer Sales Channel

During the years ended December 31, 2021, 2020 and 2019, no individual country outside the United States generated revenue that represented more than 10% of total revenue. The table below sets forth revenues for the Company’s two primary geographical markets, based on the geographic location to which its products are shipped (in thousands).


	For the Year Ended December 31,
	2021		2020		2019
United States	$	524,907	$	415,680	$	302,084
International	177,892		83,150		60,221
Total Sales	$	702,799	$	498,830	$	362,305

Sales to distributors accounted for 67%, 70%, and 73% of the Company’s total domestic sales for the years ended December 31, 2021, 2020 and 2019, respectively. Sales to distributors accounted for 95%, 94%, and 92% of the Company’s total international sales for the years ended December 31, 2021, 2020 and 2019, respectively.

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-URI http://asc.fasb.org/topic&trid=2134510

+ Details

Stockholders' Equity - Schedule of Common Stock Warrants (Details) - $ / shares	Dec. 31, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding warrants (in shares)	214,510
Common Stock Warrant Expiring October 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants exercise price (in dollars per share)	$ 3.50
Outstanding warrants (in shares)	1,000	154,700
Common Stock Warrant Expiring March 2027
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants exercise price (in dollars per share)	$ 23.50
Outstanding warrants (in shares)	193,788
Common Stock Warrant Expiring Between March 2022 and August 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants exercise price (in dollars per share)	$ 73.73
Outstanding warrants (in shares)	19,722

Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2021

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

Summary of Significant Accounting PoliciesThere have been no material changes to the Company’s significant accounting policies during the year ended December 31, 2021, other than the adoption of ASU No. 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, effective January 1, 2021 (see Note 7, “Debt”).

Use of Estimates

The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in the Company’s consolidated financial statements and accompanying notes as of the date of the consolidated financial statements. Some of those judgments can be subjective and complex, and therefore, actual results could differ materially from those estimates under different assumptions or conditions.

Cash Equivalents

The Company considers all highly liquid investments with a maturity of three months or less from the date of purchase and that can be liquidated without prior notice or penalty to be cash equivalents.

Short-Term Investments

The Company’s short-term investments are classified as available-for-sale securities. Such securities are carried at fair value as determined by prices for identical or similar securities at the balance sheet date. The Company’s short-term investments consist of Level 1 and Level 2 financial instruments in the fair value hierarchy. The net unrealized gains or losses on available-for-sale securities that are not related to credit factors are reported as a component of other comprehensive income (loss) within the statements of operations and accumulated other comprehensive income (loss) as a separate component of stockholders’ equity on the consolidated balance sheets. The Company determines realized gains or losses on the sale of available-for-sale securities using the specific identification method and includes net realized gains and losses as a component of other income or expense within the consolidated statements of operations.

The Company reviews its available-for-sale debt securities for credit losses quarterly, considering a variety of factors, including the significance of the decline in value as compared to the amortized cost basis; underlying factors contributing to a decline in the prices of securities in a single asset class; the security’s relative performance versus its peers, sector or asset class; the market and economy in general; views of external investment managers; news or financial information that has been released specific to the investee; and the outlook for the overall industry in which the investee operates. Losses on available-for-sale debt securities as a result of credit factors are recognized by recording an impairment loss as a component of other income or expense within the consolidated statements of operations and a corresponding allowance for credit losses. The Company has not recognized any impairment losses related to its short-term investments during the years ended December 31, 2021, 2020 and 2019.

Accounts Receivable

The Company grants credit to various customers in the ordinary course of business and is paid directly by customers who use its products, distributors and third-party insurance payors. The Company maintains an allowance for its current estimate of expected credit losses. Provisions for expected credit losses are estimated based on historical experience, assessment of specific risk, review of outstanding invoices, forecasts about the future, and various assumptions and estimates that are believed to be reasonable under the circumstances, which included the Company’s estimates of credit risks as a result of the coronavirus pandemic (COVID-19 global pandemic). Uncollectible accounts are written off against the allowance after appropriate collection efforts have been exhausted and when it is deemed that a balance is uncollectible.

Concentration of Credit Risk

Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash, cash equivalents, short-term investments and accounts receivable. The Company maintains deposit accounts in federally insured financial institutions in excess of federally insured limits. The Company also maintains investments in money market funds that are not federally insured. Additionally, the Company has established guidelines regarding investment instruments and their maturities, which are designed to maintain preservation of principal and liquidity.

The following table summarizes customers who accounted for 10% or more of accounts receivable, net:


	December 31,
	2021		2020
Customer A	*		12.7	%
Customer B	11.2	%	12.3	%

* Amount related to the respective customer represented less than 10% for the period presented.

The following table summarizes customers who accounted for 10% or more of total sales for the periods presented:


	Year Ended December 31,
	2021		2020		2019
Customer B	11.9	%	15.9	%	14.8	%
Customer C	*		12.9	%	15.4	%

* Amount related to the respective customer represented less than 10% for the period presented.

Fair Value of Financial Instruments

The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable, accrued expenses, and employee-related liabilities are reasonable estimates of their fair values because of the short-term nature of these assets and liabilities. Short-term investments are carried at fair value. The carrying value and estimated fair value of certain of the Company’s common stock warrants was determined using the Black-Scholes pricing model as of December 31, 2021 and 2020 (see Note 5, “Fair Value Measurements”).

The Company’s convertible senior notes are carried at amortized cost on the consolidated balance sheets (see Note 7, “Debt”). The Company determined the fair value of its convertible senior notes to be $430.0 million and $333.5 million at December 31, 2021 and 2020, respectively, based on Level 2 quoted market prices as of that date

Valuation of Inventories

Inventories are valued at the lower of cost or net realizable value, determined by the first-in, first-out method. Inventory is recorded using standard cost, including material, labor and overhead costs. The Company periodically reviews inventories for potential impairment and adjusts inventory for potentially excess or obsolete goods to state inventories at their net realizable value. Factors influencing these adjustments include quantities on hand and firm purchase commitments, expectations of future use, judgments based on quality control testing data and assessments of the likelihood of scrapping or obsoleting certain inventories based on future demand for its products and market conditions.

Long-Lived Assets

Property and Equipment

Property and equipment, which primarily consist of office furniture and equipment, manufacturing equipment, scientific equipment, computer equipment, and leasehold improvements, are stated at cost, less accumulated depreciation. Property and equipment are depreciated over the estimated useful lives of the assets, generally three to seven years, using the straight-line method. Leasehold improvements are amortized over the lesser of the estimated useful lives of the assets or the remaining lease term. Maintenance and repair costs are expensed as incurred.

Operating Lease Right-of-Use Assets and Liabilities

Lease right-of-use assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent its obligation to make lease payments arising from the lease. Operating lease right-of-use assets and liabilities are recognized when the Company takes possession of the leased property (the Commencement Date) based on the present value of lease payments over the lease term. For lease agreements entered into or reassessed after the adoption of ASC 842 Leases, the Company combines lease and non-lease components. Rent expense on noncancelable leases containing known future scheduled rent increases is recorded on a straight-line basis over the term of the respective leases beginning on the Commencement Date. The difference between rent expense and rent paid is accounted for as a component of operating lease right-of-use assets on the Company’s consolidated balance sheets. Landlord improvement allowances and other similar lease incentives are recorded as a reduction of the right-of-use leased assets, and are amortized on a straight-line basis as a reduction to operating lease costs.

Cost Basis Equity Investment

During the second quarter of 2021, the Company made an $8.1 million equity investment in a private company, which represented less than 5% of the outstanding equity of that company. The investment is recorded using the cost minus impairment adjusted for changes in observable prices and is included as a component of other long-term assets on the consolidated balance sheet at December 31, 2021. We monitor this investment to evaluate whether any increase or decline in its value has occurred, based on the implied value of recent company financings, public market prices of comparable companies and general market conditions.

Intangible Assets Subject to Amortization

Finite-lived intangible assets are recorded at cost, net of accumulated amortization and, if applicable, impairment charges. Amortization of finite-lived intangible assets is recognized over their estimated useful lives on a straight-line basis. The Company reviews its finite-lived intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company has not recognized any impairment losses during the years ended December 31, 2021, 2020 and 2019.

On June 24, 2020, the Company acquired Sugarmate, Inc. (Sugarmate), the developer of a mobile app designed to help people visualize diabetes therapy data in innovative ways. The Sugarmate acquisition was accounted for as an acquisition of assets in accordance with ASU No. 2017-01, Business Combinations (Topic 805) Clarifying the Definition of a Business. Substantially all of the fair value was concentrated in a single identifiable asset, a technology-based intangible asset. The purchased intangible asset is being amortized on a straight-line basis over an estimated useful life of five years. The Company’s results of operations include the operating results of Sugarmate since the date of acquisition, the amounts of which were not material.

Revenue Recognition

Revenue is generated primarily from sales of insulin pumps, disposable insulin cartridges and infusion sets to individual customers with third-party insurance coverage and through a network of distributors that resell the products to insulin-dependent diabetes customers. The Company recognizes revenue when it transfers control of the promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services, net of estimated returns.

Revenue Recognition for Arrangements with Multiple Performance Obligations

The Company considers the individual deliverables in its product offering as separate performance obligations. The transaction price is determined based on the consideration expected to be received, based either on the stated value in contractual arrangements or the estimated cash to be collected in non-contracted arrangements. The Company allocates the consideration to the individual performance obligations and recognizes the consideration based on when the performance obligation is satisfied, considering whether or not this occurs at a point in time or over time. Generally, insulin pumps, cartridges, infusion sets and accessories are deemed performance obligations that are satisfied at a point in time when the customer obtains control of the promised good, which typically is upon shipment for our distributor arrangements and upon receipt for sales directly to individual customers. Complementary products, such as t:connect and the Tandem Device Updater, are considered distinct performance obligations that are satisfied over time, as access and support for these products is provided throughout the typical four-year warranty period of the insulin pumps. Accordingly, revenue related to the complementary products is deferred and recognized over a four-year period. Where there is no standalone value for the complementary product, the Company determines its value by applying the expected cost plus a margin approach and then allocates the residual to the insulin pumps. Deferred revenue related to these performance obligations that are satisfied over time was included in the following consolidated balance sheet accounts in the amounts shown as of December 31, 2021 and 2020 (in thousands):


	December 31, 2021		December 31, 2020
Deferred revenue	$	9,625	$	5,508
Other long-term liabilities	16,940		10,426
Total	$	26,565	$	15,934

Sales Returns

The Company offers a 30-day right of return to customers in the U.S. and Canada from the date of shipment of its insulin pumps, provided a physician’s confirmation of the medical reason for the return is received. Estimated allowances for sales returns are based on historical returned quantities as compared to pump shipments in those same periods of return, adjusted for known or expected changes in the marketplace when appropriate. The amount recorded in deferred revenue on the Company’s consolidated balance sheets for allowances for sales returns was $0.6 million and $0.6 million at December 31, 2021 and 2020, respectively. Actual product returns have not differed materially from estimated amounts recorded in the accompanying consolidated financial statements.

Warranty Reserve

The Company generally provides a four-year warranty on its insulin pumps to end user customers and may replace any pumps that do not function as intended in accordance with the product specifications within the warranty period. Insulin pumps returned to the Company may be refurbished and redeployed. Additionally, the Company offers a six-month warranty on disposable insulin cartridges and infusion sets. Estimated warranty costs are recorded at the time of shipment, and the Company reevaluates the estimate of the warranty reserve obligation at each reporting period. Warranty costs are estimated primarily based on the current expected product replacement cost and expected replacement rates utilizing historical experience. Experience has shown that initial data for any given pump version may be insufficient; therefore, our process relies on long-term historical averages until sufficient data are available. As actual experience becomes available, we use the data to update the historical averages. The Company may make further adjustments to the warranty reserve when deemed appropriate, giving additional consideration to the length of time each pump version has been in the field and revised future expectations of performance based on new features and capabilities that may become available through Tandem Device Updater.

The following table provides a reconciliation of the changes in product warranty liabilities for the years ended December 31, 2021, 2020 and 2019 (in thousands):


	Year Ended December 31,
	2021		2020		2019
Balance at beginning of the year	$	22,075	$	16,724	$	9,138
Provision for warranties issued during the period	27,604		21,135		18,335
Settlements made during the period	(18,768)		(13,736)		(10,167)
Decrease in warranty estimates	(510)		(2,048)		(582)
Balance at end of the year	$	30,401	$	22,075	$	16,724

As of December 31, 2021 and December 31, 2020, total product warranty reserves of $30.4 million and $22.1 million, respectively, were included in the following consolidated balance sheet accounts (in thousands):


	December 31,
	2021		2020
Other current liabilities	$	13,076	$	8,409
Other long-term liabilities	17,325		13,666
Total warranty reserve	$	30,401	$	22,075

Common Stock Warrant Liabilities

The Company accounts for certain stock warrants as a liability in the consolidated financial statements when they contain a provision within the warrant contracts that could require cash settlement in the event the Company did not have an active registration statement. The fair value of these common stock warrants is remeasured at each financial reporting period with any changes in fair value being recognized as a component of other income (expense) in the accompanying statements of operations and comprehensive income (loss).

Stock-Based Compensation

Stock-based compensation cost is measured at the grant date based on the estimated fair value of the award, and the portion that is ultimately expected to vest is recognized as compensation expense over the requisite service period on a straight-line basis. The Company estimates the fair value of stock options issued under the Company’s Amended and Restated 2013 Stock Incentive Plan (2013 Plan) and the fair value of the employees’ purchase rights under the Company’s 2013 Employee Stock Purchase Plan (ESPP) using the Black-Scholes option-pricing model on the date of grant. The Black-Scholes option-pricing model requires the use of assumptions about a number of variables, including stock price volatility, expected term, dividend yield and risk-free interest rate (see Note 8, “Stockholders’ Equity”). The fair value of restricted stock unit (RSU) awards issued under the Company’s 2013 Plan that vest solely based on service is estimated based on the fair market value of the underlying stock on the date of grant. The fair value of RSU awards issued under the 2013 Plan that vest based upon the Company’s actual performance relative to predefined performance metrics is estimated based on the fair market value of the underlying stock on the date of grant and the probability that the specified performance criteria will be met, subject to the awardee’s continuing service through the measurement date. At each reporting period, we reassess the probability of the achievement of such performance metrics. Any expense change resulting from an adjustment in the estimated shares to be released is recorded in the period of adjustment.

Shipping and Handling Expenses

Shipping and handling expenses associated with product delivery are included within cost of sales in the Company’s statements of operations. Amounts billed to a customer for shipping and handling are reported as revenues.

Research and Development Costs

All research and development costs are charged to expense as incurred. Such costs include personnel-related costs, including stock-based compensation, supplies, license fees, development prototypes, outside design and testing services, depreciation, allocated facilities and information services, clinical trial costs, milestone payments under the Company’s development and commercialization agreements and other indirect costs.

Income Taxes

The Company uses the asset and liability method of accounting for income taxes. Deferred tax assets or liabilities are recognized based on the temporary differences between financial statement and income tax bases of assets and liabilities using enacted tax rates in effect for the years in which the differences are expected to reverse. Tax law and rate changes are reflected in income in the period such changes are enacted. A valuation allowance is recorded when it is more likely than not that some of the deferred tax assets will not be realized. The Company includes interest and penalties related to income taxes, including unrecognized tax benefits, within income tax expense.

The Company’s income tax returns are based on calculations and assumptions that are subject to examination by the Internal Revenue Service and other tax authorities. In addition, the calculation of the Company’s tax liabilities involves dealing with uncertainties in the application of complex tax regulations. The Company recognizes liabilities for uncertain tax positions using a two-step approach. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon settlement. While the Company believes it has appropriate support for the positions taken on its tax returns, the Company regularly assesses the potential outcomes of examinations by tax authorities in determining the adequacy of its provision for income taxes. The Company continually assesses the likelihood and amount of potential revisions and adjusts the income tax provision, income taxes payable and deferred taxes in the period in which the facts that give rise to a revision become known.

Significant judgment is required in determining the Company’s provision for income taxes, deferred tax assets and liabilities and the valuation allowance recorded against net deferred tax assets. Deferred tax assets and liabilities are determined using the enacted tax rates in effect for the years in which those tax assets are expected to be realized. A valuation allowance is established when it is more likely than not the future realization of all or some of the deferred tax assets will not be achieved. The evaluation of the need for a valuation allowance is performed on a jurisdiction-by-jurisdiction basis, and includes a review of all available positive and negative evidence. Factors reviewed include projections of pre-tax book income for the foreseeable future, determination of cumulative pre-tax book income after permanent differences, earnings history, and reliability of forecasting. The Company will continue to assess the need for a valuation allowance on its deferred tax assets by evaluating both positive and negative evidence that may exist. Any adjustment to the net deferred tax asset valuation allowance would be recorded in the statement of operations for the period that the adjustment is determined to be required.

The Company is required to file federal and state income tax returns in the United States and various other state jurisdictions, and a corporation income tax return in Canada. The preparation of these income tax returns requires the Company to interpret the applicable tax laws and regulations in effect in such jurisdictions, which could affect the amount of tax paid by the Company. An amount is accrued for the estimate of additional tax liability, including interest and penalties, for any uncertain tax positions taken or expected to be taken in an income tax return. The Company reviews and updates the accrual for uncertain tax positions as more definitive information becomes available (see Note 10, “Income Taxes.”

Comprehensive Income (Loss)

All components of comprehensive income (loss), including net income (loss), are reported in the consolidated financial statements in the period in which they are recognized. Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources, including unrealized gains and losses on marketable securities and foreign currency translation adjustments.

Net Income (Loss) Per Share

Basic net income (loss) per share is calculated by dividing the net income (loss) by the weighted average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net income per share reflects the potential dilution that would occur if securities exercisable for or convertible into common stock were exercised for or converted into common stock. Dilutive common share equivalents are comprised of stock options and unvested RSUs outstanding under the Company’s stock plans, potential awards to be granted pursuant to the ESPP, and common stock warrants, each calculated using the treasury stock method; and shares issuable upon conversion of the convertible senior notes calculated using the if-converted method. For common stock warrants that are recorded as a liability in the accompanying consolidated balance sheets, the calculation of diluted loss per share requires that, to the extent the average market price of the underlying shares for the reporting period exceeds the exercise price of the warrants and the presumed exercise of the warrants is dilutive to loss per share for the period, an adjustment is made to net loss used in the calculation to remove the change in fair value of the warrants from the numerator for the period. Likewise, an adjustment to the denominator is required to reflect the related dilutive shares, if any, under the treasury stock method.

For the years ended December 31, 2020 and 2019, there was no difference in the weighted average number of shares used to calculate basic and diluted net loss per share due to the Company’s net loss position. For the year ended December 31, 2021, the numerator and denominator of the diluted net income per share computation were calculated as follows (in thousands):


	Year Ended December 31,
	2021
Net income - basic and diluted	$	15,566



Weighted average shares outstanding - basic	63,000
Dilutive common share equivalents:
Options to purchase common stock	1,129
Unvested restricted stock units	62
Warrants to purchase common stock	157
Awards to be granted under the ESPP	1

Weighted average shares outstanding - diluted	64,349

Potentially dilutive securities outstanding and not included in the calculation of diluted net loss per share (because inclusion would be anti-dilutive) are as follows (in thousands, in common stock equivalent shares):


	Year Ended December 31,
	2021	2020	2019
Options to purchase common stock	3,124	5,021	5,619
Unvested restricted stock units	—	78	N/A
Warrants to purchase common stock	1	379	611
Awards granted under the ESPP	—	3	5
Convertible senior notes (if-converted)	2,554	1,605	N/A
	5,679	7,086	6,235

Recent Accounting Pronouncements

In June 2020, the FASB issued ASU No. 2020-06, Accounting for Convertible Instruments and Contracts in

an Entity’s Own Equity, which is intended to simplify the accounting for convertible instruments. This new guidance eliminated certain models that require separate accounting for embedded conversion features, and eliminated certain of the conditions for equity classification for contracts in an entity’s own equity. Accordingly, a convertible debt instrument will be accounted for as a single liability measured at its amortized cost, as long as no other features require bifurcation and recognition as derivatives. The new guidance could be adopted through either a modified retrospective method of transition or a fully retrospective method of transition. ASU 2020-06 is effective for public business entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted for fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The Company elected to early adopt the new standard on January 1, 2021 using the modified retrospective method and, accordingly, recorded a net reduction to accumulated deficit of $9.0 million, a decrease to additional paid-in capital of $85.8 million, and an increase to convertible senior notes, net - long-term of $76.8 million to reflect the impact of the accounting change (see Note 7, “Debt”).

Fair Value Measurements (Tables)

12 Months Ended

Dec. 31, 2021

Fair Value Disclosures [Abstract]

Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis

The following table presents information about the Company’s financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2021 and 2020, and indicates the fair value hierarchy of the valuation techniques utilized by the Company to determine such fair value (in thousands):


	Fair Value Measurements at December 31, 2021
	Total		Level 1		Level 2		Level 3
Assets
Cash equivalents (1)	$	48,286	$	48,286	$	—	$	—
U.S. Treasury securities	221,724		221,724		—		—
Commercial paper	218,381		—		218,381		—
U.S. Government-sponsored enterprises	50,686		—		50,686		—
Corporate debt securities	58,836		—		58,836		—
Supranational bonds	3,003		—		3,003		—
Total assets	$	600,916	$	270,010	$	330,906	$	—
Liabilities
Common stock warrants	$	147	$	—	$	—	$	147
Total liabilities	$	147	$	—	$	—	$	147


	Fair Value Measurements at December 31, 2020
	Total		Level 1		Level 2		Level 3
Assets
Cash equivalents (1)	$	87,300	$	87,300	$	—	$	—
U.S. Treasury securities	143,254		143,254		—		—
Commercial paper	108,896		—		108,896		—
U.S. Government-sponsored enterprises	52,350		—		52,350		—
Corporate debt securities	85,823		—		85,823		—
Total assets	$	477,623	$	230,554	$	247,069	$	—
Liabilities
Common stock warrants	$	14,261	$	—	$	—	$	14,261
Total liabilities	$	14,261	$	—	$	—	$	14,261

(1)Generally, cash equivalents include money market funds and investments with a maturity of three months or less from the date of purchase.

Schedule of Assumptions Used to Estimate Fair Values of Common Stock Warrants

. The assumptions used to estimate the fair values of the outstanding Series A warrants at December 31, 2021 and 2020 are presented below:


	Series A Warrants
	December 31, 2021		December 31, 2020
Risk-free interest rate	0.3	%	0.1	%
Expected dividend yield	0.0%		0.0%
Expected volatility	39.1	%	55.3	%
Expected term (in years)	0.8		1.8

Schedule of Changes in Fair Value of Total Level 3 Financial Assets

The following table presents a summary of changes in the fair value of the Company’s Level 3 financial liabilities for the years ended December 31, 2021 and 2020:


	2021		2020
Balance at beginning of year	$	14,261	$	23,509
Loss recognized from the change in fair value of common stock warrants	1,386		17,087
Common stock warrants exercised during the period	(15,500)		(26,335)
Balance at end of year	$	147	$	14,261

Leases - Schedule of Future Minimum Payments Under Non-cancellable Operating Leases (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Leases [Abstract]
2022	$ 9,281
2023	6,949
2024	5,744
2025	5,825
2026	5,531
Thereafter	5,144
Total undiscounted lease payments	38,474
Less: amount representing interest	(5,273)
Present value of operating lease liabilities	33,201
Less: current portion of operating lease liabilities	(9,279)	$ (9,421)
Operating lease liabilities - long-term	$ 23,922	$ 15,914

Fourth Quarter Financial Data (Unaudited) (Tables)

12 Months Ended

Dec. 31, 2021

Quarterly Financial Information Disclosure [Abstract]

Quarterly Financial Information

The financial information for the three months ended December 31, 2021 and 2020 presented in the following table reflects all normal recurring adjustments that are, in the opinion of management, necessary for a fair statement of the results of the interim periods (in thousands, except per share data):


	For the Quarter Ended
	December 31, 2021		December 31, 2020
Sales	$	209,996	$	168,065
Gross profit	$	113,729	$	90,556
Operating expenses	$	100,991	$	71,894
Operating income	$	12,738	$	18,662
Net income	$	10,808	$	17,000
Basic net income per share	$	0.17	$	0.27
Diluted net income per share	$	0.16	$	0.22

The numerator and denominator of the basic and diluted net income per share computations are calculated as follows for the three months ended December 31, 2021 and 2020:


	For the Quarter Ended
(in thousands)	December 31, 2021		December 31, 2020
Net income	$	10,808	$	17,000
Less: change in fair value of common stock warrants	32		(2,819)
Net income - diluted	$	10,840	$	14,181

Weighted average shares outstanding - basic	63,650		62,249
Dilutive common share equivalents:
Options to purchase common stock	1,877		2,984
Unvested restricted stock units	227		133
Warrants to purchase common stock	170		308
Awards to be granted under the ESPP	3		4
Convertible senior notes (if-converted)	—		—
Weighted average shares outstanding - diluted	65,927		65,678

Fair Value Measurements - Schedule of Assumptions Used to Estimate Fair Values of Common Stock Warrants (Detail) - Series A Warrants	Dec. 31, 2021	Dec. 31, 2020
Risk-free interest rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants outstanding, measurement input	0.003	0.001
Expected dividend yield
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants outstanding, measurement input	0.0	0.0
Expected volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants outstanding, measurement input	0.391	0.553
Expected term (in years)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected term (in years)	9 months 18 days	1 year 9 months 18 days

Debt

12 Months Ended

Dec. 31, 2021

Debt Disclosure [Abstract]

Debt

Convertible Senior Notes

In May 2020, the Company entered into a purchase agreement with certain counterparties for the sale of an aggregate of $287.5 million principal amount of 1.50% Convertible Senior Notes due 2025 (Notes) in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. The proceeds from the issuance of the Notes were $244.6 million, net of debt issuance costs and cash used to pay the cost of the capped call transactions (Capped Call Transactions) discussed below.

The Notes are the Company’s senior unsecured obligations. Interest is payable in cash semi-annually in arrears beginning on November 1, 2020 at a rate of 1.50% per year. The Notes mature on May 1, 2025 unless repurchased, redeemed, or converted in accordance with their terms prior to the maturity date.

The Notes are convertible into cash, shares of the Company’s common stock, or a combination of cash and shares of the Company’s common stock, at the Company’s election, at an initial conversion rate of 8.8836 shares of common stock per $1,000 principal amount of the Notes, which is equivalent to an initial conversion price of $112.57 (Conversion Price) per share of the Company’s common stock. The conversion rate is subject to customary adjustments for certain events as described in the Indenture. The Company expects to settle conversions through a combination settlement, which involves payment in cash equal to the principal portion and delivery of shares of common stock for the excess of the conversion value over the principal portion.

The Company may not redeem the Notes prior to May 6, 2023. The Company has the option to redeem for cash all or any portion of the Notes on or after May 6, 2023 if the last reported sale price of the Company’s common stock has been at least 130% of the Conversion Price then in effect for at least 20 trading days (whether or not consecutive), including the trading day immediately preceding the date on which the Company provides notice of redemption, during any 30 consecutive trading day period, at a redemption price equal to 100% of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest. No sinking fund is provided for the Notes.

Holders of the Notes may convert all or a portion of their Notes at their option prior to November 1, 2024, in multiples of $1,000 principal amounts, only under the following circumstances:

•if the last reported sale price of the Company’s common stock for at least 20 trading days (whether or not consecutive) during the period of 30 consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the applicable conversion price of the Notes on each such trading day;

•during the five business day period after any five consecutive trading day period in which the trading price per $1,000 principal amount of the Notes for each day of that five consecutive trading day period was less than 98% of the product of the last reported sale price of the Company’s common stock and the applicable conversion rate of the Notes on such trading day;

•if the Company calls any or all of the Notes for redemption, at any time prior to the close of business on the scheduled trading day immediately preceding the redemption date; or

•on the occurrence of specified corporate events.

On or after November 1, 2024, until the close of business on the second scheduled trading day immediately preceding the maturity date, holders may convert their Notes at any time, regardless of the foregoing circumstances.

Holders of the Notes who convert in connection with a make-whole fundamental change or in connection with a redemption are entitled to an increase in the conversion rate. Additionally, in the event of a fundamental change, holders of the Notes may require us to repurchase all or a portion of the Notes at a price equal to 100% of the principal amount of the Notes, plus any accrued and unpaid interest.

Initially, in accounting for the issuance of the Notes, the Company separated the Notes into liability and equity components. The carrying amount of the liability component was calculated by measuring the fair value of similar debt instruments, which do not have an associated convertible feature. The carrying amount of the equity component representing the conversion option for the Notes was $88.5 million and was recorded as a debt discount, which was being amortized to interest expense at an effective interest rate of 9.9%. In addition, the Company allocated $2.7 million of debt issuance costs to the equity component and the remaining debt issuance costs of $6.1 million were allocated to the liability component, which were being amortized to interest expense under the effective interest rate method.

On January 1, 2021, the Company early adopted ASU No. 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which is intended to simplify the accounting for convertible instruments. The ASU eliminates the cash conversion feature models in ASC 470-20, Debt with Conversion and Other Options, which required an issuer of certain convertible debt to separately account for embedded conversion features as a component of equity. Instead, an issuer will account for these securities as a single unit of account, unless the conversion feature meets certain criteria. The Company adopted the new standard using the modified retrospective method, and recorded a net reduction to accumulated deficit of $9.0 million, a decrease to additional paid-in capital of $85.8 million, and an increase to convertible senior notes, net - long-term of $76.8 million to reflect the impact of the accounting change. The Notes are now accounted for as a single liability measured at amortized cost, as no other embedded features require bifurcation and recognition as derivatives.

The liability and equity components of the Notes consisted of the following (in thousands):


	December 31, 2021		December 31, 2020
Liability:
Principal amount	$	287,500	$	287,500
Unamortized debt issuance costs	(6,033)		(5,446)
Unamortized debt discount	—		$	(79,070)
Net carrying amount	$	281,467	$	202,984
Carrying amount of the equity component	$	—	$	85,803

As of December 31, 2021, the unamortized debt issuance costs of $6.0 million associated with the Notes will be amortized to interest expense, at an effective interest rate of 2.2% over the remaining period of approximately 3.3 years.

The following table details interest expense recognized related to the Notes for the years ended December 31, 2021 and 2020 (in thousands):



	December 31, 2021		December 31, 2020
Contractual interest expense	$	4,313	$	2,707
Amortization of debt issuance costs	1,727		652
Amortization of debt discount	N/A		9,446
Total interest expense	$	6,040	$	12,805

The Notes will have a dilutive effect to the extent the average market price per share of common stock for a given reporting period exceeds the conversion price of $112.57. As of December 31, 2021, the if-converted value of the Notes exceeded the principal amount by $96.9 million. As of December 31, 2020, the “if-converted value” did not exceed the principal amount of the Notes.

Capped Call Transactions

In connection with the issuance of the Notes, the Company entered into Capped Call Transactions in May 2020 with certain counterparties at a net cost of $34.1 million. The Capped Call Transactions are intended to reduce potential dilution to holders of the Company’s common stock beyond the conversion price of $112.57, up to a conversion price of $173.18 on any conversion of the Notes, or to offset any cash payments the Company is required to make in excess of the principal amount of such converted Notes, as the case may be, with such reduction or offset subject to a cap. The cap price of the Capped Call Transactions is initially $173.18 per share of the Company’s common stock, representing a premium of 100% above the last reported sale price of $86.59 per share of the Company’s common stock on May 12, 2020, and is subject to certain adjustments under the terms of the Capped Call Transactions. Conditions that cause adjustments to the initial strike price of the Capped Call Transactions mirror conditions that result in corresponding adjustments for the Notes.

For accounting purposes, the Capped Call Transactions are separate transactions, and not part of the terms of the Notes, while they are integrated for federal tax purposes. As these transactions met certain criteria under the applicable accounting guidance, the Capped Call Transactions were recorded in stockholders' equity and were not accounted for as derivatives. The cost of the Capped Call Transactions was recorded as a reduction of the Company’s additional paid-in capital in the Company’s consolidated balance sheet and will not be remeasured.

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-URI http://asc.fasb.org/topic&trid=2208564

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1E
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

+ Details

Employee Benefits	12 Months Ended
Employee Benefits	Dec. 31, 2021
Retirement Benefits [Abstract]
Employee Benefits	Employee Benefits Employee 401(k) Plan The Company has a defined contribution 401(k) plan for employees in the United States who are at least 18 years of age. Employees are eligible to participate in the plan beginning on the first day of the calendar month following their date of hire. Unless they affirmatively elect otherwise, employees are automatically enrolled in the plan following 30 days from date of rehire or entry date. Under the terms of the plan, employees may make voluntary contributions as a percent of compensation, and the Company may elect to match a discretionary percentage of employee contributions. The Company did not provide a matching contribution during the three years ended December 31, 2021, but approved a discretionary match to begin in 2022.

Stockholders' Equity (Tables)

12 Months Ended

Dec. 31, 2021

Equity [Abstract]

Schedule of Shares of Common Stock Reserved for Future Issuance

The following shares of the Company's common stock were reserved for future issuance at December 31, 2021 (in thousands):


Shares reserved for issuance upon conversion of Convertible Senior Notes			2,554
Shares underlying outstanding warrants			215
Shares underlying outstanding stock options			4,814
Shares underlying unvested restricted stock units			612
Shares authorized for issuance pursuant to awards granted under the ESPP			1,216
Shares authorized for future equity award grants			1,382
			10,793

Schedule of Stockholders' Equity Common Stock Warrants

Warrants outstanding to purchase shares of the Company's common stock as of December 31, 2021 were as follows:


Issue Date	Exercise Price Per Share	Warrants Outstanding	Expiration Date of Warrants Outstanding
October 2017	$3.50	1,000	October 2022
March 2017	$23.50	193,788	March 2027
August 2011 - August 2012	$73.73	19,722	May 2022 - August 2022
		214,510

Schedule of Stock Option Activities for 2006 Plan and 2013 Plan

The following table summarizes stock option activities for the 2006 Plan and 2013 Plan:


	Total Options	Weighted- Average Exercise Price Per Share		Weighted- Average Remaining Contractual Life (in years)	Aggregate Intrinsic Value (in thousands)
Outstanding at December 31, 2019	7,174,927	$	38.40	8.45	$	181,408
Granted	1,130,040	$	83.55
Exercised	(2,339,467)	$	24.69		$	161,688
Canceled/forfeited/expired	(161,995)	$	27.00		$	4,516
Outstanding at December 31, 2020	5,803,505	$	52.08	7.90	$	268,649
Granted	355,008	$	86.68
Exercised	(1,128,791)	$	37.05		$	86,149
Canceled/forfeited/expired	(215,372)	$	76.29		$	6,963
Outstanding at December 31, 2021	4,814,350	$	57.08	7.07	$	452,081
Vested and expected to vest at December 31, 2021	4,769,317	$	56.95	7.06	$	448,460
Exercisable at December 31, 2021	3,013,030	$	49.28	6.50	$	307,235

Schedule of Restricted Stock Units

A summary of RSU activity for the years ended December 31, 2021 and 2020 is as follows:


	Total RSUs	Weighted-Average Grant Date Fair Value		Aggregate Intrinsic Value (in thousands)
Unvested awards outstanding at December 31, 2019	—	$	—	$	—
Granted	134,694	$	82.82
Vested	(1,892)	$	95.68
Unvested awards outstanding at December 31, 2020	132,802	$	82.82	$	12,706
Granted	564,034	$	96.37
Vested	(53,957)	$	82.74
Canceled/forfeited	(30,705)	$	87.21
Unvested awards outstanding at December 31, 2021	612,174	$	95.11	$	92,144

Schedule of Compensation Cost Included in Consolidated Statement of Operations

The following table summarizes the allocation of stock-based compensation expense included in the consolidated statements of operations for all stock-based compensation arrangements (in thousands):


	Year Ended December 31,
	2021		2020		2019
Cost of sales	$	6,434	$	8,210	$	6,415
Selling, general & administrative	43,567		41,563		42,857
Research and development	10,751		8,658		8,799
Total stock-based compensation expense	$	60,752	$	58,431	$	58,071

Schedule of Assumptions Used in Black-Scholes Option-Pricing Model

The assumptions used in the Black-Scholes option-pricing model are as follows:


	Stock Options
	Year Ended December 31,
	2021			2020			2019
Weighted average grant date fair value (per share)	$	56.89		$	54.20		$	39.06
Risk-free interest rate	1.0		%	0.6		%	2.1		%
Expected dividend yield	0.0		%	0.0		%	0.0		%
Expected volatility	75.1		%	74.6		%	71.8		%
Expected term (in years)	6.1			6.1			6.0


	ESPP
	Year Ended December 31,
	2021			2020			2019
Weighted average grant date fair value (per share)	$	38.19		$	36.83		$	30.32
Risk-free interest rate	0.2		%	0.2		%	1.9		%
Expected dividend yield	0.0		%	0.0		%	0.0		%
Expected volatility	44.2		%	60.3		%	69.9		%
Expected term (in years)	1.3			1.3			1.3

Fair Value Measurements

12 Months Ended

Dec. 31, 2021

Fair Value Disclosures [Abstract]

Fair Value Measurements

Fair Value MeasurementsAuthoritative guidance on fair value measurements defines fair value, and provides a consistent framework for measuring fair value and for disclosures of each major asset and liability category measured at fair value on either a recurring or a nonrecurring basis. Fair value is intended to reflect an assumed exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the authoritative guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:


Level 1:						Observable inputs such as unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.

Level 2:						Inputs, other than quoted prices in active markets, that are observable either directly or indirectly for substantially the full term of the asset or liability.

Level 3:						Unobservable inputs in which there is little or no market data and that are significant to the fair value of the assets or liabilities, which require the reporting entity to develop its own valuation techniques that require input assumptions.


	Fair Value Measurements at December 31, 2021
	Total		Level 1		Level 2		Level 3
Assets
Cash equivalents (1)	$	48,286	$	48,286	$	—	$	—
U.S. Treasury securities	221,724		221,724		—		—
Commercial paper	218,381		—		218,381		—
U.S. Government-sponsored enterprises	50,686		—		50,686		—
Corporate debt securities	58,836		—		58,836		—
Supranational bonds	3,003		—		3,003		—
Total assets	$	600,916	$	270,010	$	330,906	$	—
Liabilities
Common stock warrants	$	147	$	—	$	—	$	147
Total liabilities	$	147	$	—	$	—	$	147


	Fair Value Measurements at December 31, 2020
	Total		Level 1		Level 2		Level 3
Assets
Cash equivalents (1)	$	87,300	$	87,300	$	—	$	—
U.S. Treasury securities	143,254		143,254		—		—
Commercial paper	108,896		—		108,896		—
U.S. Government-sponsored enterprises	52,350		—		52,350		—
Corporate debt securities	85,823		—		85,823		—
Total assets	$	477,623	$	230,554	$	247,069	$	—
Liabilities
Common stock warrants	$	14,261	$	—	$	—	$	14,261
Total liabilities	$	14,261	$	—	$	—	$	14,261

(1)Generally, cash equivalents include money market funds and investments with a maturity of three months or less from the date of purchase.

The Company’s Level 2 financial instruments are valued using market prices on less active markets with observable valuation inputs such as interest rates and yield curves. The Company obtains the fair value of Level 2 financial instruments from quoted market prices, calculated prices or quotes from third-party pricing services. The Company validates these prices through independent valuation testing and review of portfolio valuations provided by the Company’s investment managers.

The Company's Level 3 liabilities at December 31, 2021 and 2020 included the remaining Series A warrants issued by the Company in connection with the public offering of common stock in October 2017. The Series A warrants, which expire in October 2022, provide holders the right to purchase shares of the Company’s common stock at an exercise price of $3.50 per share. As of December 31, 2021 and 2020, there were Series A warrants outstanding to purchase 1,000 shares and 154,700 shares, respectively, of the Company’s common stock (see Note 8, “Stockholders’ Equity”).

The Company reassesses the fair value of the outstanding Series A warrants at each reporting date utilizing a Black-Scholes pricing model. Variables used in the pricing model include the closing market price of the Company’s common stock at the balance sheet date, as well as estimated stock price volatility, dividend yield, remaining warrant term and risk-free interest rate. A significant increase (decrease) in any of these inputs in isolation, particularly the market price of the Company’s common stock, would have resulted in a significantly higher (lower) fair value measurement. The assumptions used to estimate the fair values of the outstanding Series A warrants at December 31, 2021 and 2020 are presented below:


	Series A Warrants
	December 31, 2021		December 31, 2020
Risk-free interest rate	0.3	%	0.1	%
Expected dividend yield	0.0%		0.0%
Expected volatility	39.1	%	55.3	%
Expected term (in years)	0.8		1.8

The following table presents a summary of changes in the fair value of the Company’s Level 3 financial liabilities for the years ended December 31, 2021 and 2020:


	2021		2020
Balance at beginning of year	$	14,261	$	23,509
Loss recognized from the change in fair value of common stock warrants	1,386		17,087
Common stock warrants exercised during the period	(15,500)		(26,335)
Balance at end of year	$	147	$	14,261

Of the loss recognized from the change in fair value of common stock warrants for the years ended December 31, 2021 and 2020, $0.1 million and $5.5 million, respectively, was attributable to warrants outstanding as of December 31, 2021 and 2020.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Leases

12 Months Ended

Dec. 31, 2021

Leases [Abstract]

Leases

The Company's leases consist of operating leases for general office space, laboratory, manufacturing and warehouse facilities, and equipment. These noncancellable operating leases have initial lease terms from two years to twelve years, eight months. Leases with an initial term of 12 months or less are expensed as incurred and are not recorded as right-of-use assets on the Company’s consolidated balance sheets. The Company is required to recognize operating lease right-of-use assets and liabilities, and begin recording lease expense when the Company takes possession of the leased property (the Commencement Date). The Company recognizes lease expense for these leases on a straight-line basis over the lease term. Because the Company’s leases do not provide an implicit interest rate, the Company uses its incremental borrowing rate based on the information available at the lease Commencement Date to determine the operating lease right-of-use assets and liabilities based on the present value of future lease payments over the lease term. The Company used the incremental borrowing rate on January 1, 2019 for operating leases that commenced prior to that date.

Certain leases include an option to renew, with renewal terms that can extend the lease term for additional periods. The exercise of lease renewal options is at the Company’s sole discretion. For renewal options that are reasonably certain at the lease Commencement Date of being exercised, the Company includes the renewal option period in the lease term. The depreciable life of assets and leasehold improvements are limited by the expected lease term, unless there is a transfer of title or purchase option that is reasonably certain to be exercised.

In November 2019, the Company entered into a lease agreement for approximately 94,562 square feet of additional general office space located on Shoreline Drive, in Boise, Idaho (Shoreline Lease). The lease term began in July 2020, and expires in June 2027. The Company has a one-time option to extend the term of the Shoreline Lease for a period of three years. The Company recognized right-of-use leased assets and corresponding operating lease liabilities of approximately $6.5 million on the consolidated balance sheet on the Commencement Date in the first quarter of 2020.

In January 2020, the Company entered into a sublease agreement for approximately 30,703 square feet of general office space located on High Bluff Drive, in San Diego, California (High Bluff Sublease). The lease term began in April 2020 and expires in March 2022. The Company recognized right-of-use leased assets and corresponding operating lease liabilities of approximately $2.3 million on the consolidated balance sheet on the Commencement Date in the first quarter of 2020.

In September 2020, the Company amended certain leases covering four separate buildings that comprise in aggregate 77,458 square feet of general office and laboratory space located on Roselle Street in San Diego, California (Roselle Street Leases). The lease amendments extended the term of each lease for an additional period of one year, and included a rent increase during the additional lease term. The Roselle Street Leases, which would have expired in May 2022, are now scheduled to expire in May 2023. The Company recognized additional right-of-use leased assets and corresponding operating lease liabilities of $2.2 million on the consolidated balance sheet in the third quarter of 2020 related to the amendment of the Roselle Street Leases.

In March 2021, the Company entered into a second amendment (Second Amendment) to its lease agreement for office space located on Vista Sorrento Parkway in San Diego, California (Vista Sorrento Lease) covering 59,013 square feet of general administrative office space (Existing Premises). The Second Amendment expanded the Existing Premises by adding 14,916 square feet of general administrative office space (Expansion Space), and extended the lease term for the Existing Premises through January 2028. The Expansion Space lease Commencement Date occurred in March 2021, and the lease term expires in January 2028. The Company has two options to extend the term of the Vista Sorrento Lease, covering both the Existing Premises and the Expansion Space, with each option providing for an additional period of five years. The Vista Sorrento Lease term was determined assuming the renewal options would not be exercised. The Company recognized right-of-use leased assets and corresponding operating lease liabilities of $15.1 million on the consolidated balance sheet in the first quarter of 2021 related to the Second Amendment.

The Company’s lease costs recorded in the consolidated statements of operations were as follows (in thousands):


	Year Ended December 31,
	2021		2020		2019
Operating lease cost	$	8,627	$	7,514	$	4,542
Short-term lease cost	90		219		165
Total lease cost	$	8,717	$	7,733	$	4,707

Maturities of operating lease liabilities at December 31, 2021 were as follows (in thousands):


Years Ending December 31,
2022	$	9,281
2023	6,949
2024	5,744
2025	5,825
2026	5,531
Thereafter	5,144
Total undiscounted lease payments	38,474
Less: amount representing interest	(5,273)
Present value of operating lease liabilities	33,201
Less: current portion of operating lease liabilities	(9,279)
Operating lease liabilities - long-term	$	23,922

The weighted-average remaining lease term and weighted-average discount rate for operating leases were as follows:


	December 31, 2021		December 31, 2020
Weighted-average remaining lease term (in years)	5.0		3.7
Weighted-average discount rate used to determine operating lease liabilities	5.6	%	5.9	%

Cash paid for amounts included in the measurement of lease liabilities, representing operating cash flows from operating leases, was $9.5 million and $8.2 million for the years ended December 31, 2021 and 2020, respectively.

Leases For Which Accounting Has Not Yet Commenced

As of December 31, 2021, the Commencement Date for the High Bluff and Tech Center Leases described below, had not yet occurred. Accordingly, the consolidated balance sheet at December 31, 2021 does not include operating lease right-of-use assets and operating lease liabilities, and the consolidated statement of operations for the year ended December 31, 2021 does not include any lease costs, related to the High Bluff Lease and the Tech Center Lease. In addition, the above disclosures of the Company’s lease costs, maturities of operating lease liabilities, and the weighted-average remaining lease term and weighted-average discount rate, do not include any amounts related to the High Bluff and Tech Center Leases.

High Bluff Lease

In May 2021, the Company entered into a lease agreement for approximately 31,372 square feet of general office space located on High Bluff Drive, in San Diego, California (High Bluff Lease). The High Bluff Lease is a direct lease agreement for the same property subject to the High Bluff Sublease. The lease term begins in April 2022 following the termination of the High Bluff Sublease in March 2022, and is scheduled to expire in March 2024. The Company expects to recognize right-of-use leased assets and corresponding operating lease liabilities of approximately $3.0 million on the consolidated balance sheet on the Commencement Date in the second quarter of 2022.

Tech Center Lease

In September 2021, the Company entered into a lease agreement for 181,949 square feet of additional general administrative, laboratory, and research and development office space (the Premises) located on High Bluff Drive in San Diego, California (Tech Center Lease). Possession of the Premises is expected to be tendered to the Company by the landlord in two phases, with Phase I consisting of 143,850 rentable square feet, and Phase II consisting of 38,099 rentable square feet. The Company intends to use Phase I of the Tech Center Lease for operations currently located at the Roselle Street Leases.

The initial lease term Phase I Commencement Date will occur on the date the Company is tendered possession of the Phase I portion of the Premises (which is currently expected to be in March 2022), and rent payments commence six months thereafter (the Phase I Rent Commencement Date). The Phase II Commencement Date is expected to occur upon the earlier of (i) the date upon which the Company first commences business in the Phase II portion of the Premises, and (ii) May 1, 2025 (the Phase II Rent Commencement Date). The lease will expire twelve years, eight months from the first day of the first full month following the Phase I Rent Commencement Date. The Company has two options to extend the term of the lease, with each option providing for an additional period of five years, by delivering written notice to the landlord in accordance with the terms of the Tech Center Lease.

The Tech Center Lease also includes a first right of offer with respect to an additional 34,569 rentable square feet of general office space should the space become available. The lease term and associated base rent for the additional space will not be known until the Company is notified that the additional space has become available, and the Company elects to lease the space on terms mutually satisfactory to the Company and the landlord.

The initial base rent for the Tech Center Lease is approximately $906,000 per month beginning on the Phase I Rent Commencement Date, and the base rent increases by approximately $255,000 per month on the Phase II Rent Commencement Date. The monthly base rent will increase annually by 3.0% on each annual anniversary of the respective Rent Commencement Date. In addition to the monthly base rent, the Company is required to pay its proportionate share of certain ongoing operating expenses throughout the duration of the lease. No base rent, other than the proportionate share of operating expenses, will be due for the Phase I portion of the Premises for months two through nine of the initial lease term, and for the Phase II portion of the Premises for months two through five following the Phase II Rent Commencement Date.


Years Ending December 31,	High Bluff Lease(1)		Tech Center Lease(2)		Total
2022	$	1,029	$	—	$	1,029
2023	1,594		6,453		8,047
2024	403		11,313		11,716
2025	—		12,694		12,694
2026	—		15,181		15,181
2027 through 2035	—		145,583		145,583
Total	$	3,026	$	191,224	$	194,250

(1) The Company currently estimates that the Commencement Date will occur in the second quarter of 2022, at which time the operating lease right-of-use assets and liabilities will be recorded.

Business Segment and Geographic Information - Additional Information (Detail) - segment	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Revenue, Major Customer [Line Items]
Number of operating segments	1
United States \| Revenue from Contract with Customer Benchmark \| Customer Concentration Risk
Revenue, Major Customer [Line Items]
Customers accounted for 10% or more	67.00%	70.00%	73.00%
International \| Revenue from Contract with Customer Benchmark \| Customer Concentration Risk
Revenue, Major Customer [Line Items]
Customers accounted for 10% or more	95.00%	94.00%	92.00%

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 71,181	$ 94,613
Short-term investments	552,630	390,323
Accounts receivable, net	110,725	82,195
Inventories	68,551	63,721
Prepaid and other current assets	8,433	6,383
Total current assets	811,520	637,235
Property and equipment, net	50,386	50,022
Operating lease right-of-use assets	27,503	19,773
Other long-term assets	15,728	9,385
Total assets	905,137	716,415
Current liabilities:
Accounts payable	28,032	17,805
Accrued expenses	9,419	4,783
Employee-related liabilities	51,556	34,159
Deferred revenue	10,182	6,082
Common stock warrants	147	14,261
Operating lease liabilities	9,279	9,421
Other current liabilities	23,241	17,341
Total current liabilities	131,856	103,852
Convertible senior notes, net - long-term	281,467	202,984
Operating lease liabilities - long-term	23,922	15,914
Other long-term liabilities	34,780	27,360
Total liabilities	472,025	350,110
Commitments and contingencies (Note 12)	0	0
Stockholders’ equity:
Common stock, $0.001 par value; 200,000 shares authorized, 63,833 and 62,335 shares issued and outstanding at December 31, 2021 and December 31, 2020, respectively.	64	62
Additional paid-in capital	1,068,259	1,025,233
Accumulated other comprehensive income (loss)	(616)	220
Accumulated deficit	(634,595)	(659,210)
Total stockholders’ equity	433,112	366,305
Total liabilities and stockholders’ equity	$ 905,137	$ 716,415

Business Segment and Geographic Information - Geographical Markets (Detail) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disaggregation of Revenue [Line Items]
Total Sales	$ 209,996	$ 168,065	$ 702,799	$ 498,830	$ 362,305
United States
Disaggregation of Revenue [Line Items]
Total Sales			524,907	415,680	302,084
International
Disaggregation of Revenue [Line Items]
Total Sales			$ 177,892	$ 83,150	$ 60,221

- Definition

+ References

+ Details

Leases - Schedule of Lease Cost, Lease Term Discount Rate ,Operating Leases (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Leases [Abstract]
Operating lease cost	$ 8,627	$ 7,514	$ 4,542
Short-term lease cost	90	219	165
Total lease cost	$ 8,717	$ 7,733	$ 4,707
Weighted-average remaining lease term (in years)	5 years	3 years 8 months 12 days
Weighted-average discount rate used to determine operating lease liabilities	5.60%	5.90%

Leases - Future Minimum Payments For Monthly Base Rent Due Under the Initial Lease Term (Details) $ in Thousands	Dec. 31, 2021 USD ($)
Lessee, Lease, Description [Line Items]
2022	$ 9,281
2023	6,949
2024	5,744
2025	5,825
2026	5,531
2027 through 2035	5,144
Total undiscounted lease payments	38,474
High Bluff Drive And Tech Center Lease
Lessee, Lease, Description [Line Items]
2022	1,029
2023	8,047
2024	11,716
2025	12,694
2026	15,181
2027 through 2035	145,583
Total undiscounted lease payments	194,250
High Bluff Drive Lease
Lessee, Lease, Description [Line Items]
2022	1,029
2023	1,594
2024	403
2025	0
2026	0
2027 through 2035	0
Total undiscounted lease payments	3,026
Tech Center Lease
Lessee, Lease, Description [Line Items]
2022	0
2023	6,453
2024	11,313
2025	12,694
2026	15,181
2027 through 2035	145,583
Total undiscounted lease payments	$ 191,224

Stockholders' Equity - Additional Information (Detail) $ in Millions	1 Months Ended	12 Months Ended
	Oct. 31, 2013 purchase_period	Dec. 31, 2021 USD ($) shares	Dec. 31, 2020 USD ($) shares	Jun. 30, 2019 shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares issued by each warrant		1
Options, exercised (in shares)		1,128,791	2,339,467
Total stock-based compensation expense capitalized as part of cost of inventory \| $		$ 1.0	$ 0.6
Unrecognized compensation expense \| $		$ 129.2
Share-based payment arrangement, cost not yet recognized, period for recognition		2 years 7 months 6 days
Options to purchase common stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options, exercised (in shares)		1,128,791	2,339,467
Maximum term of stock options (in years)		10 years
Vesting period		4 years
Vesting period of remaining stock (in years)		3 years
Options to purchase common stock \| First Anniversary of Vesting Date \| 2013 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock vested percentage		25.00%
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares issued in period upon vesting (in shares)		38,156	1,892
Vested (in share)		53,957	1,892
Vesting period		4 years
Granted (in shares)		564,034	134,694
Restricted Stock Units (RSUs) \| First Anniversary of Vesting Date \| 2013 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock vested percentage		25.00%
Restricted Stock Units (RSUs) \| Monthly vesting over following 3 years \| 2013 Plan \| Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period		3 years
Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)		25,674
Warrants to purchase common stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants issue to purchase common stock (in shares)		155,517	295,526
2013 Stock Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares of authorized for issuance (in shares)				5,000,000
ESPP
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period		2 years
Maximum percentage that employee can contribute for purchase of common stock	15.00%
Offering period	2 years
Number of purchase periods \| purchase_period	4
Purchase period	6 months
Purchase of common stock under ESPP (in shares)		172,694	302,509
Proceeds from stock plans \| $		$ 11.1	$ 9.1
ESPP \| Date of Offering
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Purchase price of common stock on date of purchase	85.00%
ESPP \| Date of Purchase
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Purchase price of common stock on date of purchase	85.00%

Stockholders' Equity - Schedule of Assumptions Used in Black-Scholes Option-Pricing Model (Detail) - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average grant date fair value (in dollars per share)	$ 56.89	$ 54.20	$ 39.06
Risk-free interest rate	1.00%	0.60%	2.10%
Expected dividend yield	0.00%	0.00%	0.00%
Expected volatility	75.10%	74.60%	71.80%
Expected term (in years)	6 years 1 month 6 days	6 years 1 month 6 days	6 years
ESPP
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average grant date fair value (in dollars per share)	$ 38.19	$ 36.83	$ 30.32
Risk-free interest rate	0.20%	0.20%	1.90%
Expected dividend yield	0.00%	0.00%	0.00%
Expected volatility	44.20%	60.30%	69.90%
Expected term (in years)	1 year 3 months 18 days	1 year 3 months 18 days	1 year 3 months 18 days

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Dec. 31, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	200,000,000	200,000,000
Common stock, shares issued (in shares)	63,833,000	62,335,000
Common stock, shares outstanding (in shares)	63,833,000	62,335,000

Employee-Benefits - Additional Information (Detail)	12 Months Ended
Employee-Benefits - Additional Information (Detail)	Dec. 31, 2021
Retirement Benefits [Abstract]
Minimum age of employees for defined contribution plan	18 years

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Statement [Abstract]
Sales	$ 702,799	$ 498,830	$ 362,305
Cost of sales	326,584	238,310	168,093
Gross profit	376,215	260,520	194,212
Operating expenses:
Selling, general and administrative	261,508	204,903	165,735
Research and development	92,054	63,574	45,199
Total operating expenses	353,562	268,477	210,934
Operating income (loss)	22,653	(7,957)	(16,722)
Other income (expense), net:
Interest income and other, net	674	1,567	3,193
Interest expense	(6,040)	(12,805)	0
Change in fair value of common stock warrants	(1,386)	(17,087)	(11,075)
Total other expense, net	(6,752)	(28,325)	(7,882)
Income (loss) before income taxes	15,901	(36,282)	(24,604)
Income tax expense (benefit)	335	(1,900)	149
Net income (loss)	15,566	(34,382)	(24,753)
Other comprehensive income (loss):
Unrealized gain (loss) on short-term investments	(693)	(20)	77
Foreign currency translation gain (loss)	(143)	118	58
Comprehensive income (loss)	$ 14,730	$ (34,284)	$ (24,618)
Net income (loss) per share - basic (in dollars per share)	$ 0.25	$ (0.56)	$ (0.42)
Net income (loss) per share - diluted (in dollars per share)	$ 0.24	$ (0.56)	$ (0.42)
Weighted average shares used to compute basic net income (loss) per share (in shares)	63,000	60,990	58,507
Weighted average shares used to compute diluted net income (loss) per share (in shares)	64,349	60,990	58,507

Commitments and Contingencies	12 Months Ended
Commitments and Contingencies	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Legal and Regulatory Matters In April 2020, the Company was named as a defendant in four federal class action lawsuits relating to a data breach it experienced in January 2020, each of which was subsequently dismissed. In addition, in May 2020 the Company was named as a defendant in three California state court class action lawsuits arising from the same data breach. Collectively, these lawsuits seek statutory, compensatory, actual, and punitive damages; equitable relief, including restitution; pre- and post-judgment interest; injunctive relief; and attorney fees, costs, and expenses from the Company. On July 24, 2020, these three pending lawsuits were consolidated into a single case in the Superior Court of the State of California in the County of San Bernardino entitled Joseph Deluna et al v. Tandem Diabetes Care, Inc. The consolidated case alleges violations of the Confidentiality of Medical Information Act (CMIA), California Consumer Privacy Act (CCPA), California’s Unfair Competition Law (UCL), and breach of contract. The Company filed a demurrer seeking dismissal of all claims, which was heard by the Court on October 27, 2020, and which resulted in the following outcome: (i) the demurrer of the CMIA claim was denied; (ii) the demurrer of the CCPA claim was sustained; and (iii) the demurrer of the UCL and contract claims were sustained with leave to amend the pending complaint. A second demurrer was heard by the Court on March 29, 2021 with the following outcome: (i) the demurrer of the CMIA claim was denied; and (ii) the demurrer of the UCL and contract claims were narrowed in scope to dismiss three plaintiffs for either failing to allege cognizable damages or injuries-in-fact, resulting in two remaining plaintiffs. Although the Company intends to vigorously defend against these claims, there is no guarantee that the Company will prevail. The Company presently is unable to determine the ultimate outcome of these lawsuits or determine the amount (or range) of possible losses associated with the lawsuits. In September 2020, the Company was named as a defendant in a lawsuit entitled Buck Walsh, individually and on behalf of others similarly situated v. Tandem Diabetes Care, Inc., which was filed in the Superior Court of the State of California in the County of San Diego. The alleged violations include business and professions code and labor code violations for failure to compensate wages, unpaid meal and rest periods, and failure to reimburse for necessary business-related expenses. The case was brought as a class action and was later amended to also include a representative action under the California Private Attorney General Act, or PAGA. The class of plaintiffs includes hourly paid or non-exempt employees of the Company who were employed from April 6, 2016 through the date of adjudication. The parties recently agreed to resolve all claims in the lawsuit. The settlement of claims covered by the PAGA matter were approved by the Superior Court of the State of California in the County of San Diego on September 21, 2021 and settlement amounts were disbursed in 2021. In October 2021, a settlement of the class action related claims was preliminarily approved by an independent arbitrator mutually acceptable to both parties. The class action is intended to resolve the claims of the individual plaintiff, as well as the remaining members of the class, unless an individual class member submits a timely request for exclusion. The material terms of the settlement are set forth in a binding Memorandum of Agreement dated as of July 1, 2021, which is subject to the completion of a number of conditions, as well as final approval by the independent arbitrator. There is no guarantee that the conditions will be met or that final approval will be obtained. If the final class settlement is not approved, or if other conditions to approval of the settlement are not met, the case will continue and the Company will continue to vigorously defend against the claims. From time to time, the Company is involved in various other legal proceedings, regulatory matters, and other disputes or claims arising from or related to the normal course of our business activities, including actions with respect to intellectual property, data privacy, employment, regulatory, product liability and contractual matters. Although the results of legal proceedings, disputes and other claims cannot be predicted with certainty, the Company believes it is not currently a party to any legal proceeding(s) which, if determined adversely to the Company, would, individually or taken together, have a material adverse effect on the Company’s business, operating results, financial condition or cash flows. However, regardless of the merit of the claims raised or the outcome, legal proceedings may have an adverse impact on the Company as a result of defense and settlement costs, diversion of management time and resources, and other factors. Except as set forth above, as of December 31, 2021 and December 31, 2020, there were no legal proceedings, regulatory matters, or other disputes or claims for which a material loss was considered probable or for which the amount (or range) of loss was reasonably estimable. However, regardless of the merits of the claims raised or the outcome, legal proceedings, regulatory matters, and other disputes and claims may have an adverse impact on the Company because of as a result of defense and settlement costs, diversion of management time and resources, and other factors. Letters of Credit The Company leases general office space, laboratory, manufacturing and warehouse facilities, and equipment under noncancelable operating leases for use in our operations (see Note 6, “Leases”). In connection with one of the operating leases, the Company has a $4.9 million unsecured irrevocable standby letter of credit arrangement with a bank, under which the landlord of the building is the beneficiary. The Company is required to maintain the standby letter of credit throughout the term of the lease, which is currently expected to expire in April 2035. Purchase Obligations The Company has agreements with suppliers and other parties to purchase inventory, other goods and services and long-lived assets. Product inventory obligations consist primarily of purchase order commitments for raw materials used in the production of insulin pumps and cartridges, and finished goods infusion sets. Cancellation of outstanding purchase orders is generally allowed under the standard terms of our purchase order agreements, but may require payment of costs incurred through the date of cancellation. At December 31, 2021, obligations under our purchase agreements totaled approximately $255 million, of which approximately $251 million is scheduled to be received and become payable within one-year.

Composition of Certain Financial Statement Items - Reconciliation of Change in Estimated Allowance for Doubtful Accounts (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Allowance for doubtful accounts
Balance at beginning of the year	$ 3,857	$ 3,304	$ 1,837
Provision for expected credit losses	2,333	3,016	2,322
Write-offs and adjustments, net of recoveries	(1,941)	(2,463)	(855)
Balance at end of the year	$ 4,249	$ 3,857	$ 3,304

Fourth Quarter Financial Data (Unaudited)

12 Months Ended

Dec. 31, 2021

Quarterly Financial Information Disclosure [Abstract]

Fourth Quarter Financial Data (Unaudited)

Quarter Financial Data (Unaudited)


	For the Quarter Ended
	December 31, 2021		December 31, 2020
Sales	$	209,996	$	168,065
Gross profit	$	113,729	$	90,556
Operating expenses	$	100,991	$	71,894
Operating income	$	12,738	$	18,662
Net income	$	10,808	$	17,000
Basic net income per share	$	0.17	$	0.27
Diluted net income per share	$	0.16	$	0.22

The numerator and denominator of the basic and diluted net income per share computations are calculated as follows for the three months ended December 31, 2021 and 2020:


	For the Quarter Ended
(in thousands)	December 31, 2021		December 31, 2020
Net income	$	10,808	$	17,000
Less: change in fair value of common stock warrants	32		(2,819)
Net income - diluted	$	10,840	$	14,181

Weighted average shares outstanding - basic	63,650		62,249
Dilutive common share equivalents:
Options to purchase common stock	1,877		2,984
Unvested restricted stock units	227		133
Warrants to purchase common stock	170		308
Awards to be granted under the ESPP	3		4
Convertible senior notes (if-converted)	—		—
Weighted average shares outstanding - diluted	65,927		65,678

Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Jun. 30, 2021	Jan. 01, 2021	Dec. 31, 2018
Summary Of Significant Accounting Policies [Line Items]
Investment owned at cost				$ 8,100,000
Ownership interest of investment owned				5.00%
Finite lived intangible assets impairment loss	$ 0	$ 0	$ 0
Offered period for sales return	30 days
Allowance for product returns	$ 600,000	600,000
Warranty reserve	30,401,000	22,075,000	$ 16,724,000			$ 9,138,000
Accumulated deficit	(634,595,000)	(659,210,000)
Convertible senior notes, net - long-term	$ 281,467,000	202,984,000
Slim cartridges and infusion sets
Summary Of Significant Accounting Policies [Line Items]
Warranty period offered	6 months
Insulin Pump
Summary Of Significant Accounting Policies [Line Items]
Warranty period offered	4 years
Technology-Based Intangible Assets
Summary Of Significant Accounting Policies [Line Items]
Estimated useful life	5 years
Cumulative Effect, Period of Adoption, Adjustment \| Accounting Standards Update 2020-06
Summary Of Significant Accounting Policies [Line Items]
Accumulated deficit					$ 9,000,000
Additional paid in capital					(85,800,000)
Convertible senior notes, net - long-term					$ 76,800,000
Minimum
Summary Of Significant Accounting Policies [Line Items]
Estimated useful lives of the assets	3 years
Maximum
Summary Of Significant Accounting Policies [Line Items]
Estimated useful lives of the assets	7 years
Convertible senior notes \| Level 2 \| Convertible senior notes
Summary Of Significant Accounting Policies [Line Items]
Convertible senior notes, fair value	$ 430,000,000	$ 333,500,000

Short-Term Investments - Summary of Estimated Fair Value of Short-Term Investments (Detail) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Cash Cash Equivalents And Short Term Investments [Line Items]
Amortized Cost	$ 553,254	$ 390,254
Gross Unrealized Gain	15	86
Gross Unrealized Loss	(639)	(17)
Estimated Fair Value	552,630	390,323
U.S. Treasury securities
Cash Cash Equivalents And Short Term Investments [Line Items]
Amortized Cost	222,206	143,244
Gross Unrealized Gain	0	12
Gross Unrealized Loss	(482)	(2)
Estimated Fair Value	221,724	143,254
Commercial paper
Cash Cash Equivalents And Short Term Investments [Line Items]
Amortized Cost	218,391	108,892
Gross Unrealized Gain	14	5
Gross Unrealized Loss	(24)	(1)
Estimated Fair Value	218,381	108,896
Corporate debt securities
Cash Cash Equivalents And Short Term Investments [Line Items]
Amortized Cost	58,881	85,788
Gross Unrealized Gain	0	48
Gross Unrealized Loss	(45)	(13)
Estimated Fair Value	58,836	85,823
U.S. Government-sponsored enterprises
Cash Cash Equivalents And Short Term Investments [Line Items]
Amortized Cost	50,773	52,330
Gross Unrealized Gain	1	21
Gross Unrealized Loss	(88)	(1)
Estimated Fair Value	50,686	$ 52,350
Supranational bonds
Cash Cash Equivalents And Short Term Investments [Line Items]
Amortized Cost	3,003
Gross Unrealized Gain	0
Gross Unrealized Loss	0
Estimated Fair Value	$ 3,003

Income Taxes - Schedule of Unrecognized Tax Benefits (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Gross unrecognized tax benefits at the beginning of the year	$ 10,107	$ 6,580	$ 8,824
Increases related to current year positions	3,482	2,234	1,076
Increases (decreases) related to prior year positions	0	1,293	(3,320)
Gross unrecognized tax benefits at the end of the year	$ 13,589	$ 10,107	$ 6,580

Fourth Quarter Financial Data (Unaudited) - Basic and Diluted Net Income (Loss) Per Share (Detail) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Net income	$ 10,808	$ 17,000	$ 15,566	$ (34,382)	$ (24,753)
Less: change in fair value of common stock warrants	32	(2,819)
Net income - diluted	$ 10,840	$ 14,181	$ 15,566
Weighted average shares outstanding - basic (in shares)	63,650	62,249	63,000	60,990	58,507
Dilutive common share equivalents:
Common stock (in shares)			157
Weighted average shares outstanding - diluted (in shares)	65,927	65,678	64,349	60,990	58,507
Options to purchase common stock
Dilutive common share equivalents:
Common stock (in shares)	1,877	2,984
Unvested restricted stock units
Dilutive common share equivalents:
Common stock (in shares)	227	133
Warrants to purchase common stock
Dilutive common share equivalents:
Common stock (in shares)	170	308
Awards to be granted under the ESPP
Dilutive common share equivalents:
Unvested and granted (in shares)	3	4
Convertible senior notes (if-converted)
Dilutive common share equivalents:
Convertible senior notes (if-converted) (in shares)	0	0

Composition of Certain Financial Statement Items - Summary of Inventory (Detail) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Raw materials	$ 26,911	$ 30,880
Work-in-process	16,612	15,664
Finished goods	25,028	17,177
Total inventories	$ 68,551	$ 63,721

Commitments and Contingencies (Detail) $ in Millions		1 Months Ended		12 Months Ended
Commitments and Contingencies (Detail) $ in Millions	Mar. 29, 2021 Plaintiff	May 31, 2020 lawsuit	Apr. 30, 2020 lawsuit	Dec. 31, 2021 USD ($) legal_matter	Dec. 31, 2020 legal_matter
Commitments and Contingencies Disclosure [Abstract]
Number of lawsuits \| lawsuit		3	4
Number of plaintiffs to dismiss contract claims \| Plaintiff	3
Loss contingency, number of plaintiffs \| Plaintiff	2
Number of legal proceedings regulatory matters or other disputes or claims \| legal_matter				0	0
Unsecured standby letter of credit				$ 4.9
Purchase obligation				255.0
Purchase obligation due within one year				$ 251.0

Fair Value Measurements - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Outstanding warrants (in shares)	214,510
Loss recognized from the change in fair value of common stock warrants	$ 1,386	$ 17,087
Common Stock Warrant Expiring October 2022
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Stock price per share (in dollars per share)	$ 3.50
Outstanding warrants (in shares)	1,000	154,700
Loss recognized from the change in fair value of common stock warrants	$ 100	$ 5,500

Organization and Basis of Presentation (Policies)

12 Months Ended

Dec. 31, 2021

Organization, Consolidation and Presentation of Financial Statements [Abstract]

The Company

Tandem Diabetes Care, Inc. is a medical device company focused on the design, development and commercialization of technology solutions for people living with diabetes. Tandem Diabetes Care, Inc. is incorporated in the state of Delaware. Unless the context requires otherwise, the terms the “Company” or “Tandem” refer to Tandem Diabetes Care, Inc., together with its wholly-owned subsidiaries in the U.S. and Canada.

The Company manufactures, sells and supports insulin pump products that are designed to address the evolving needs and preferences of differentiated segments of the insulin-dependent diabetes market. The Company’s manufacturing, sales and support activities principally focus on the t:slim X2 Insulin Delivery System (t:slim X2), the Company’s flagship pump platform which is capable of remote software updates and is designed to display continuous glucose monitoring (CGM) sensor information directly on the pump home screen. The Company’s insulin pump products are compatible with other complementary digital health offerings, such as the t:connect cloud-based diabetes management application (t:connect) and the Tandem Device Updater, a Mac and PC-compatible tool which offers and supports updates of the Company’s insulin pump software from a personal computer. The Company’s insulin pump products are generally considered durable medical equipment and have an expected lifespan of at least four years. In addition to insulin pumps, the Company sells disposable products that are used together with the pumps and are replaced every few days, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to a user’s body, as well as other accessories for enhanced usability.

Basis of Presentation and Principles of Consolidation

The Company has prepared the accompanying consolidated financial statements in accordance with accounting principles generally accepted in the United States of America, or U.S. GAAP. The statements include the accounts of Tandem Diabetes Care, Inc. and its wholly-owned subsidiaries in the U.S. and Canada. All significant intercompany balances and transactions have been eliminated in consolidation.

The functional currency of the Company’s foreign subsidiary is the local currency. The Company translates the financial statements of its foreign subsidiary into U.S. dollars using period-end exchange rates for assets and liabilities and average exchange rates for each period for revenue, costs and expenses. Translation related adjustments are included in other comprehensive income (loss), and in accumulated other comprehensive income (loss) in the stockholders’ equity section of the Company’s consolidated balance sheets. Foreign exchange gains or losses resulting from balances denominated in a currency other than the functional currency are recognized in interest income and other, net in the Company’s consolidated statements of operations.

Use of Estimates

Cash Equivalents

Short-Term Investments

Accounts Receivable

Concentration of Credit Risk

Fair Value of Financial Instruments

Valuation of Inventories

Long-Lived Assets

Property and Equipment

Operating Lease Right-of-Use Assets and Liabilities

Intangible Assets Subject to Amortization

Research and Development Costs

Income Taxes

Revenue Recognition, Shipping and Handling Expenses

Revenue Recognition

Revenue Recognition for Arrangements with Multiple Performance Obligations


	December 31, 2021		December 31, 2020
Deferred revenue	$	9,625	$	5,508
Other long-term liabilities	16,940		10,426
Total	$	26,565	$	15,934

Sales Returns

Shipping and Handling Expenses

Warranty Reserve

Stock-Based Compensation

Common Stock Warrant Liabilities

Common Stock Warrant LiabilitiesThe Company accounts for certain stock warrants as a liability in the consolidated financial statements when they contain a provision within the warrant contracts that could require cash settlement in the event the Company did not have an active registration statement. The fair value of these common stock warrants is remeasured at each financial reporting period with any changes in fair value being recognized as a component of other income (expense) in the accompanying statements of operations and comprehensive income (loss).

Comprehensive Income (Loss)

Net Income (Loss) Per Share

Recent Accounting Pronouncements

In June 2020, the FASB issued ASU No. 2020-06, Accounting for Convertible Instruments and Contracts in

Segment Reporting

Debt - Components of Convertible Note (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020	May 31, 2020
Debt Instrument [Line Items]
Unamortized debt issuance costs		$ (8,809,000)
Convertible senior notes \| Convertible senior notes
Debt Instrument [Line Items]
Principal amount	$ 287,500,000	287,500,000	$ 287,500,000
Unamortized debt issuance costs	(6,033,000)	(5,446,000)
Unamortized debt discount	0	(79,070,000)
Net carrying amount	$ 281,467,000	202,984,000
Carrying amount of the equity component		$ 85,803,000	$ 88,500,000

- Definition

Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.

+ References + Details

Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2021

Accounting Policies [Abstract]

Summary of Customers Accounted for 10% or More

The following table summarizes customers who accounted for 10% or more of accounts receivable, net:


	December 31,
	2021		2020
Customer A	*		12.7	%
Customer B	11.2	%	12.3	%

* Amount related to the respective customer represented less than 10% for the period presented.

The following table summarizes customers who accounted for 10% or more of total sales for the periods presented:


	Year Ended December 31,
	2021		2020		2019
Customer B	11.9	%	15.9	%	14.8	%
Customer C	*		12.9	%	15.4	%

* Amount related to the respective customer represented less than 10% for the period presented.

Schedule of Contract with Customer, Contract Asset, Contract Liability, and Receivable

Deferred revenue related to these performance obligations that are satisfied over time was included in the following consolidated balance sheet accounts in the amounts shown as of December 31, 2021 and 2020 (in thousands):


	December 31, 2021		December 31, 2020
Deferred revenue	$	9,625	$	5,508
Other long-term liabilities	16,940		10,426
Total	$	26,565	$	15,934

Summary of Reconciliation of Change in Estimated Warranty Liabilities

The following table provides a reconciliation of the changes in product warranty liabilities for the years ended December 31, 2021, 2020 and 2019 (in thousands):


	Year Ended December 31,
	2021		2020		2019
Balance at beginning of the year	$	22,075	$	16,724	$	9,138
Provision for warranties issued during the period	27,604		21,135		18,335
Settlements made during the period	(18,768)		(13,736)		(10,167)
Decrease in warranty estimates	(510)		(2,048)		(582)
Balance at end of the year	$	30,401	$	22,075	$	16,724


	December 31,
	2021		2020
Other current liabilities	$	13,076	$	8,409
Other long-term liabilities	17,325		13,666
Total warranty reserve	$	30,401	$	22,075

Schedule of Earnings Per Share, Basic and Diluted

For the year ended December 31, 2021, the numerator and denominator of the diluted net income per share computation were calculated as follows (in thousands):


	Year Ended December 31,
	2021
Net income - basic and diluted	$	15,566



Weighted average shares outstanding - basic	63,000
Dilutive common share equivalents:
Options to purchase common stock	1,129
Unvested restricted stock units	62
Warrants to purchase common stock	157
Awards to be granted under the ESPP	1

Weighted average shares outstanding - diluted	64,349

Schedule of Anti-Dilutive Securities


	Year Ended December 31,
	2021	2020	2019
Options to purchase common stock	3,124	5,021	5,619
Unvested restricted stock units	—	78	N/A
Warrants to purchase common stock	1	379	611
Awards granted under the ESPP	—	3	5
Convertible senior notes (if-converted)	2,554	1,605	N/A
	5,679	7,086	6,235

Composition of Certain Financial Statement Items - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Depreciation and amortization expense related to property and equipment	$ 11.7	$ 9.2	$ 5.7
Amortization expense related to intangible assets	2.2	$ 1.2	$ 0.3
Estimated annual amortization for 2022	1.9
Estimated annual amortization for 2023	1.9
Estimated annual amortization for 2024	1.9
Estimated annual amortization for 2025	$ 0.9

Stockholders' Equity

12 Months Ended

Dec. 31, 2021

Equity [Abstract]

Stockholders' Equity

Stockholders’ Equity

Shares Reserved for Future Issuance

The following shares of the Company's common stock were reserved for future issuance at December 31, 2021 (in thousands):


Shares reserved for issuance upon conversion of Convertible Senior Notes			2,554
Shares underlying outstanding warrants			215
Shares underlying outstanding stock options			4,814
Shares underlying unvested restricted stock units			612
Shares authorized for issuance pursuant to awards granted under the ESPP			1,216
Shares authorized for future equity award grants			1,382
			10,793

Common Stock Warrants

Warrants outstanding to purchase shares of the Company's common stock as of December 31, 2021 were as follows:


Issue Date	Exercise Price Per Share	Warrants Outstanding	Expiration Date of Warrants Outstanding
October 2017	$3.50	1,000	October 2022
March 2017	$23.50	193,788	March 2027
August 2011 - August 2012	$73.73	19,722	May 2022 - August 2022
		214,510

Each warrant allows the holder to purchase one share of the Company's common stock at the exercise price per share of the respective warrant. The Company issued 155,517 and 295,526 shares of its common stock upon the exercise of warrants during the years ended December 31, 2021 and 2020, respectively.

Stock Plans

The Company’s Amended and Restated 2013 Stock Incentive Plan (2013 Plan) was originally approved by the Company’s board of directors in October 2013. Under the 2013 Plan, the Company may grant stock options, stock appreciation rights, restricted stock and restricted stock units to individuals who are then employees, officers, directors or consultants of the Company. In June 2019, the Company received approval from its stockholders to increase the number of shares of its common stock reserved for issuance under the 2013 Plan by an additional 5,000,000 shares.

The Company issued 1,128,791 and 2,339,467 shares of its common stock, respectively, upon the exercise of stock options during the years ended December 31, 2021 and 2020. During the years ended December 31, 2021 and 2020, the Company issued 38,156 and 1,892 shares of its common stock, respectively, upon the vesting of RSUs.

Common Stock Options

The maximum term of stock options granted under the 2006 Plan and 2013 Plan is ten years. Common stock options have an exercise price equal to the closing price of the Company's common stock on the applicable award date, and generally vest over a four year period as to 25% of the underlying shares on the first anniversary of the award, with the balance of the options vesting monthly over the following three years.

The following table summarizes stock option activities for the 2006 Plan and 2013 Plan:


	Total Options	Weighted- Average Exercise Price Per Share		Weighted- Average Remaining Contractual Life (in years)	Aggregate Intrinsic Value (in thousands)
Outstanding at December 31, 2019	7,174,927	$	38.40	8.45	$	181,408
Granted	1,130,040	$	83.55
Exercised	(2,339,467)	$	24.69		$	161,688
Canceled/forfeited/expired	(161,995)	$	27.00		$	4,516
Outstanding at December 31, 2020	5,803,505	$	52.08	7.90	$	268,649
Granted	355,008	$	86.68
Exercised	(1,128,791)	$	37.05		$	86,149
Canceled/forfeited/expired	(215,372)	$	76.29		$	6,963
Outstanding at December 31, 2021	4,814,350	$	57.08	7.07	$	452,081
Vested and expected to vest at December 31, 2021	4,769,317	$	56.95	7.06	$	448,460
Exercisable at December 31, 2021	3,013,030	$	49.28	6.50	$	307,235

Restricted Stock Units

Restricted stock units (RSUs) have a grant price equal to the closing price of the Company’s common stock on the award date, and generally vest over a four year period based only on service as to 25% of the underlying shares on the first anniversary of the award, with the balance of the RSUs vesting quarterly over the following three years. In addition, the Company granted 25,674 performance-based RSUs during the year ended December 31, 2021. The performance-based RSUs have a grant value equal to the closing price of the Company’s common stock on the award date, and vest upon the Company’s actual performance relative to predefined performance metrics and subject to the awardee’s continuing service through the December 31, 2024 measurement date. A summary of RSU activity for the years ended December 31, 2021 and 2020 is as follows:


	Total RSUs	Weighted-Average Grant Date Fair Value		Aggregate Intrinsic Value (in thousands)
Unvested awards outstanding at December 31, 2019	—	$	—	$	—
Granted	134,694	$	82.82
Vested	(1,892)	$	95.68
Unvested awards outstanding at December 31, 2020	132,802	$	82.82	$	12,706
Granted	564,034	$	96.37
Vested	(53,957)	$	82.74
Canceled/forfeited	(30,705)	$	87.21
Unvested awards outstanding at December 31, 2021	612,174	$	95.11	$	92,144

Employee Stock Purchase Plan

In October 2013, the Company adopted the ESPP, which enables eligible employees to purchase shares of the Company’s common stock using their after-tax payroll deductions, subject to certain conditions. The ESPP is intended to qualify as an “employee stock purchase plan” within the meaning of Section 423 of the Code. Eligible employees may contribute, through payroll deductions, up to 15% of their earnings for the purchase of common stock under the ESPP. The purchase price of common stock under the ESPP is the lesser of: (a) 85% of the fair market value of a share of the Company’s common stock on the first date of an offering or (b) 85% of the fair market value of a share of the Company’s common stock on the date of purchase. Generally, the ESPP consists of a two-year offering period with four six-month purchase periods.

During the years ended December 31, 2021 and 2020, 172,694 shares and 302,509 shares of our common stock, respectively, were purchased under the ESPP for proceeds of $11.1 million and $9.1 million, respectively.

Stock-Based Compensation

The following table summarizes the allocation of stock-based compensation expense included in the consolidated statements of operations for all stock-based compensation arrangements (in thousands):


	Year Ended December 31,
	2021		2020		2019
Cost of sales	$	6,434	$	8,210	$	6,415
Selling, general & administrative	43,567		41,563		42,857
Research and development	10,751		8,658		8,799
Total stock-based compensation expense	$	60,752	$	58,431	$	58,071

The total stock-based compensation capitalized as part of the cost of the Company’s inventories was $1.0 million and $0.6 million at December 31, 2021 and 2020, respectively.

At December 31, 2021, the total unamortized stock-based compensation expense of approximately $129.2 million will be recognized over the remaining weighted average vesting term of approximately 2.6 years.

The assumptions used in the Black-Scholes option-pricing model are as follows:


	Stock Options
	Year Ended December 31,
	2021			2020			2019
Weighted average grant date fair value (per share)	$	56.89		$	54.20		$	39.06
Risk-free interest rate	1.0		%	0.6		%	2.1		%
Expected dividend yield	0.0		%	0.0		%	0.0		%
Expected volatility	75.1		%	74.6		%	71.8		%
Expected term (in years)	6.1			6.1			6.0


	ESPP
	Year Ended December 31,
	2021			2020			2019
Weighted average grant date fair value (per share)	$	38.19		$	36.83		$	30.32
Risk-free interest rate	0.2		%	0.2		%	1.9		%
Expected dividend yield	0.0		%	0.0		%	0.0		%
Expected volatility	44.2		%	60.3		%	69.9		%
Expected term (in years)	1.3			1.3			1.3

Risk-free Interest Rate. The risk-free interest rate assumption was based on the United States Treasury’s rates for U.S. Treasury zero-coupon bonds with maturities similar to those of the expected term of the award being valued.

Expected Dividend Yield. The expected dividend yield is zero because the Company has never declared or paid any cash dividends and does not presently plan to pay cash dividends in the foreseeable future.

Expected Volatility. The expected volatility for 2021 was estimated based on a weighted-average of the Company’s actual historical volatility of its common stock measured over the expected term. During 2020, the Company transitioned to solely using the expected volatility of its own common stock. Prior to this transition, the expected volatility was estimated based on a weighted-average of the Company’s actual historical volatility since its initial public offering in November 2013, and the historical stock volatilities of a peer group of similar companies whose share prices were publicly available. The peer group consisted of publicly traded companies in the same industry and in a similar stage of development.

Expected Term. The Company utilized the simplified method for estimating the expected term of stock option grants. Under this approach, the weighted-average expected term is presumed to be the average of the vesting term and the contractual term of the option. The Company estimates the expected term of the ESPP using expected life for each tranche during the two-year offering period.

The Company also estimates forfeitures at the time of grant, and revises those estimates in subsequent periods if actual forfeitures differ from its estimates. Historical data was used to estimate pre-vesting option forfeitures and record stock-based compensation expense only for those awards that are expected to vest.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI http://asc.fasb.org/topic&trid=2208762

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 16
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

+ Details

Composition of Certain Financial Statement Items - Summary of Accounts Receivable (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accounts receivable	$ 114,974	$ 86,052
Less: allowance for credit losses	(4,249)	(3,857)	$ (3,304)	$ (1,837)
Accounts receivable, net	$ 110,725	$ 82,195

Business Segment and Geographic Information (Tables)

12 Months Ended

Dec. 31, 2021

Segment Reporting [Abstract]

Schedule of Disaggregation of Revenue

The table below sets forth revenues for the Company’s two primary geographical markets, based on the geographic location to which its products are shipped (in thousands).


	For the Year Ended December 31,
	2021		2020		2019
United States	$	524,907	$	415,680	$	302,084
International	177,892		83,150		60,221
Total Sales	$	702,799	$	498,830	$	362,305

Stockholders' Equity - Summary of Stock Option Activities for 2006 Plan and 2013 Plan (Detail) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Total Options
Options, Outstanding at beginning of period (in shares)	5,803,505	7,174,927
Options, Granted (in shares)	355,008	1,130,040
Options, Exercised (in shares)	(1,128,791)	(2,339,467)
Options, Canceled/forfeited (in shares)	(215,372)	(161,995)
Options, Outstanding at end of period (in shares)	4,814,350	5,803,505	7,174,927
Options, Vested and expected to vest at December 31, 2021 (in shares)	4,769,317
Options, Exercisable at December 31, 2021 (in shares)	3,013,030
Weighted- Average Exercise Price Per Share
Weighted-Average Exercise Price Per Share, Outstanding at beginning of period (in dollars per share)	$ 52.08	$ 38.40
Weighted-Average Exercise Price Per Share, Granted (in dollars per share)	86.68	83.55
Weighted-Average Exercise Price Per Share, Exercised (in dollars per share)	37.05	24.69
Weighted-Average Exercise Price Per Share, Canceled/forfeited (in dollars per share)	76.29	27.00
Weighted-Average Exercise Price Per Share, Outstanding at end of period (in dollars per share)	57.08	$ 52.08	$ 38.40
Weighted-Average Exercise Price Per Share, Vested and expected to vest at December 31, 2021 (in dollars per share)	56.95
Weighted-Average Exercise Price Per Share, Exercisable at December 31, 2021 (in dollars per share)	$ 49.28
Weighted-Average Remaining Contractual Life, Outstanding	7 years 25 days	7 years 10 months 24 days	8 years 5 months 12 days
Weighted-Average Remaining Contractual Life, Vested and expected to vest at December 31, 2021	7 years 21 days
Weighted-Average Remaining Contractual Life, Exercisable at December 31, 2021	6 years 6 months
Aggregate intrinsic value outstanding balance	$ 452,081	$ 268,649	$ 181,408
Aggregate Intrinsic Value, Exercised	86,149	161,688
Aggregate Intrinsic Value, Canceled/forfeited/expired	6,963	$ 4,516
Aggregate Intrinsic Value, Vested and expected to vest at December 31, 2021	448,460
Aggregate Intrinsic Value, Exercisable at December 31, 2021	$ 307,235

Summary of Significant Accounting Policies - Summary of Reconciliation of Change in Estimated Warranty Liabilities (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Movement in Standard and Extended Product Warranty Accrual, Increase (Decrease) [Roll Forward]
Balance at beginning of the year	$ 22,075	$ 16,724	$ 9,138
Provision for warranties issued during the period	27,604	21,135	18,335
Settlements made during the period	(18,768)	(13,736)	(10,167)
Decrease in warranty estimates	(510)	(2,048)	(582)
Balance at end of the year	30,401	22,075	16,724
Other current liabilities	13,076	8,409
Other long-term liabilities	17,325	13,666
Total warranty reserve	$ 30,401	$ 22,075	$ 16,724

Stockholders' Equity - Summary for Allocation of Stock-Based Compensation Expense (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	$ 60,752	$ 58,431	$ 58,071
Cost of sales
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	6,434	8,210	6,415
Selling, general & administrative
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	43,567	41,563	42,857
Research and development
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	$ 10,751	$ 8,658	$ 8,799

Composition of Certain Financial Statement Items

12 Months Ended

Dec. 31, 2021

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Composition of Certain Financial Statement Items

Accounts Receivable

Accounts receivable, net consisted of the following at (in thousands):


	December 31,
	2021		2020
Accounts receivable	$	114,974	$	86,052
Less: allowance for credit losses	(4,249)		(3,857)
Accounts receivable, net	$	110,725	$	82,195

Allowance for Credit Losses

The following table provides a reconciliation of the changes in the allowance for estimated accounts receivable credit losses for the years ended December 31, 2021, 2020 and 2019 (in thousands):


	Year Ended December 31,
	2021		2020		2019
Balance at beginning of the year	$	3,857	$	3,304	$	1,837
Provision for expected credit losses	2,333		3,016		2,322
Write-offs and adjustments, net of recoveries	(1,941)		(2,463)		(855)
Balance at end of the year	$	4,249	$	3,857	$	3,304

Inventories

Inventories consisted of the following at (in thousands):


	December 31,
	2021		2020
Raw materials	$	26,911	$	30,880
Work-in-process	16,612		15,664
Finished goods	25,028		17,177
Total inventories	$	68,551	$	63,721

Property and Equipment

Property and equipment, net consisted of the following at (in thousands):


	December 31,
	2021		2020
Leasehold improvements	$	25,245	$	22,834
Office furniture and equipment	9,943		9,876
Computer equipment and software	11,544		12,219
Manufacturing and scientific equipment	52,823		44,026
Total cost	99,555		88,955
Less: accumulated depreciation and amortization	(49,169)		(38,933)
Total property and equipment, net	$	50,386	$	50,022

Depreciation and amortization expense related to property and equipment was $11.7 million, $9.2 million, and $5.7 million for the years ended December 31, 2021, 2020, and 2019, respectively.

Intangible Assets Subject to Amortization


	December 31,
	2021		2020
Intangible assets, gross amount	$	12,502	$	12,502
Accumulated amortization	(5,866)		(3,697)
Intangible assets, net	$	6,636	$	8,805
Weighted average remaining amortization period (in months)	41		52

Amortization expense related to intangible assets subject to amortization amounted to $2.2 million, $1.2 million and $0.3 million for the years ended December 31, 2021, 2020, and 2019, respectively. The amortization expense is recorded in cost of sales and selling, general and administrative expense in the consolidated statement of operations. The estimated aggregate amortization expense for each of the five succeeding years is $1.9 million for 2022, $1.9 million for 2023, $1.9 million for 2024, and the remaining $0.9 million in 2025

Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Deferred tax assets:
Net operating loss (NOL) carryforwards	$ 78,961	$ 86,898
Research and development tax credits carryforwards	16,761	11,261
Capitalized research and development expenses	5,135	6,840
Accrued compensation	28,970	24,038
Lease liabilities	8,012	6,112
Other	20,608	12,096
Total deferred tax assets	158,447	147,245
Deferred tax liabilities:
Convertible senior notes	0	(11,224)
Fixed assets	(3,847)	(7,675)
Other	(8,177)	(6,719)
Total deferred tax liabilities	(12,024)	(25,618)
Less valuation allowance	(146,423)	(121,627)
Net deferred tax assets	$ 0	$ 0

Organization and Basis of Presentation (Detail)	12 Months Ended
Organization and Basis of Presentation (Detail)	Dec. 31, 2021
Insulin Pump \| Minimum
Organization And Basis Of Presentation [Line Items]
Expected life span term	4 years

Composition of Certain Financial Statement Items - Intangible Assets Subject to Amortization (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Indefinite-lived Intangible Assets [Line Items]
Weighted average remaining amortization period (in months)	41 months	52 months
Patents
Indefinite-lived Intangible Assets [Line Items]
Intangible assets, gross amount	$ 12,502	$ 12,502
Accumulated amortization	(5,866)	(3,697)
Intangible assets, net	$ 6,636	$ 8,805

Leases - Additional Information (Details)	12 Months Ended
Leases - Additional Information (Details)	Dec. 31, 2021 USD ($) ft² extension	Dec. 31, 2020 USD ($)	Jun. 30, 2022 USD ($)	Sep. 30, 2021 ft²	May 31, 2021 ft²	Mar. 31, 2021 USD ($) ft² extension	Sep. 30, 2020 USD ($) ft² building	Mar. 31, 2020 USD ($)	Jan. 31, 2020 ft²	Nov. 30, 2019 ft² extension
Lessee, Lease, Description [Line Items]
Operating lease right-of-use assets	$ 27,503,000	$ 19,773,000
Operating lease, liability	33,201,000
Operating lease, payments	$ 9,500,000	$ 8,200,000
Number of buildings leased \| building							4
Vista Sorrento Parkway Lease
Lessee, Lease, Description [Line Items]
Operating lease, number of options to extend \| extension						2
Operating lease extension period						5 years
Operating lease right-of-use assets						$ 15,100,000
Operating lease, liability						$ 15,100,000
Vista Sorrento Parkway Lease, Existing Premises
Lessee, Lease, Description [Line Items]
Area of office space leased \| ft²						59,013
Vista Sorrento Parkway Lease, Expansion Space
Lessee, Lease, Description [Line Items]
Area of office space leased \| ft²						14,916
Shoreline Drive, Boise, Idaho
Lessee, Lease, Description [Line Items]
Area of office space leased \| ft²										94,562
Operating lease, number of options to extend \| extension										1
Operating lease extension period										3 years
Operating lease right-of-use assets								$ 6,500,000
Operating lease, liability								6,500,000
High Bluff Drive, San Diego, California
Lessee, Lease, Description [Line Items]
Area of office space leased \| ft²									30,703
Operating lease right-of-use assets								2,300,000
Operating lease, liability								$ 2,300,000
Roselle Street San Diego California
Lessee, Lease, Description [Line Items]
Area of office space leased \| ft²							77,458
Operating lease extension period							1 year
Operating lease right-of-use assets							$ 2,200,000
Operating lease, liability							$ 2,200,000
High Bluff Drive Lease
Lessee, Lease, Description [Line Items]
Area of office space leased \| ft²					31,372
High Bluff Drive Lease \| Forecast
Lessee, Lease, Description [Line Items]
Operating lease right-of-use assets			$ 3,000,000
Operating lease, liability			$ 3,000,000
Tech Center Lease
Lessee, Lease, Description [Line Items]
Lease term	12 years 8 months
Area of office space leased \| ft²	34,569			181,949
Operating lease, number of options to extend \| extension	2
Operating lease extension period	5 years
Monthly base rent	$ 906,000
Annual percentage increase in monthly base rent	3.00%
Tech Center Lease \| Phase 2
Lessee, Lease, Description [Line Items]
Increase in monthly base rent	$ 255,000
Tech Center Lease Phase I
Lessee, Lease, Description [Line Items]
Area of office space leased \| ft²				143,850
Rent commencement period	6 months
Beginning period after initial lease term for which no rent is due	2 months
Ending period for which no rent is due	9 months
Tech Center Lease Phase II
Lessee, Lease, Description [Line Items]
Area of office space leased \| ft²				38,099
Beginning period after initial lease term for which no rent is due	2 months
Ending period for which no rent is due	5 months
Minimum
Lessee, Lease, Description [Line Items]
Lease term	2 years
Maximum
Lessee, Lease, Description [Line Items]
Lease term	12 years 8 months

Debt - Interest Expense Recognized (Details) - Convertible senior notes - Convertible senior notes - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2021	Dec. 31, 2020
Debt Instrument [Line Items]
Contractual interest expense		$ 4,313	$ 2,707
Amortization of debt issuance costs		1,727	652
Amortization of debt discount			9,446
Total interest expense		$ 6,040	$ 12,805

Stockholders' Equity - Restricted Stock Units (RSUs) (Detail) - Restricted Stock Units (RSUs) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Total RSUs
Nonvested awards outstanding at beginning balance (in shares)	132,802	0
Granted (in shares)	564,034	134,694
Vested (in shares)	(53,957)	(1,892)
Canceled/forfeited/expired (in shares)	(30,705)
Nonvested awards outstanding at ending balance (in shares)	612,174	132,802
Weighted-Average Grant Date Fair Value
Nonvested awards outstanding at beginning balance (in dollars per share)	$ 82.82	$ 0
Granted (in dollars per share)	96.37	82.82
Vested (in dollars per share)	82.74	95.68
Canceled/forfeited/expired (in dollars per share)	87.21
Nonvested awards outstanding at ending balance (in dollars per share)	$ 95.11	$ 82.82
Aggregate intrinsic value outstanding balance	$ 92,144	$ 12,706

Stockholders' Equity - Schedule of Shares of Common Stock Reserved for Future Issuance (Detail) shares in Thousands	Dec. 31, 2021 shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserved for future issuance (in shares)	10,793
Shares reserved for issuance upon conversion of Convertible Senior Notes
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserved for future issuance (in shares)	2,554
Shares underlying outstanding warrants
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserved for future issuance (in shares)	215
Shares underlying outstanding stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserved for future issuance (in shares)	4,814
Shares underlying unvested restricted stock units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserved for future issuance (in shares)	612
Shares authorized for issuance pursuant to awards granted under the ESPP
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserved for future issuance (in shares)	1,216
Shares authorized for future equity award grants
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserved for future issuance (in shares)	1,382

Organization and Basis of Presentation	12 Months Ended
Organization and Basis of Presentation	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Basis of Presentation	Organization and Basis of Presentation The Company Tandem Diabetes Care, Inc. is a medical device company focused on the design, development and commercialization of technology solutions for people living with diabetes. Tandem Diabetes Care, Inc. is incorporated in the state of Delaware. Unless the context requires otherwise, the terms the “Company” or “Tandem” refer to Tandem Diabetes Care, Inc., together with its wholly-owned subsidiaries in the U.S. and Canada. The Company manufactures, sells and supports insulin pump products that are designed to address the evolving needs and preferences of differentiated segments of the insulin-dependent diabetes market. The Company’s manufacturing, sales and support activities principally focus on the t:slim X2 Insulin Delivery System (t:slim X2), the Company’s flagship pump platform which is capable of remote software updates and is designed to display continuous glucose monitoring (CGM) sensor information directly on the pump home screen. The Company’s insulin pump products are compatible with other complementary digital health offerings, such as the t:connect cloud-based diabetes management application (t:connect) and the Tandem Device Updater, a Mac and PC-compatible tool which offers and supports updates of the Company’s insulin pump software from a personal computer. The Company’s insulin pump products are generally considered durable medical equipment and have an expected lifespan of at least four years. In addition to insulin pumps, the Company sells disposable products that are used together with the pumps and are replaced every few days, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to a user’s body, as well as other accessories for enhanced usability. Basis of Presentation and Principles of Consolidation The Company has prepared the accompanying consolidated financial statements in accordance with accounting principles generally accepted in the United States of America, or U.S. GAAP. The statements include the accounts of Tandem Diabetes Care, Inc. and its wholly-owned subsidiaries in the U.S. and Canada. All significant intercompany balances and transactions have been eliminated in consolidation. The functional currency of the Company’s foreign subsidiary is the local currency. The Company translates the financial statements of its foreign subsidiary into U.S. dollars using period-end exchange rates for assets and liabilities and average exchange rates for each period for revenue, costs and expenses. Translation related adjustments are included in other comprehensive income (loss), and in accumulated other comprehensive income (loss) in the stockholders’ equity section of the Company’s consolidated balance sheets. Foreign exchange gains or losses resulting from balances denominated in a currency other than the functional currency are recognized in interest income and other, net in the Company’s consolidated statements of operations.

Income Taxes - Income Tax Expense (Benefit) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Income tax benefit at federal statutory rate	$ 3,339	$ (7,619)	$ (5,167)
State income tax, net of federal benefit	(254)	(2,792)	(1,174)
Warrants revaluation	356	3,588	2,326
Research and development credits	(5,703)	(5,330)	(2,091)
Section 382 limitation	(97)	1,021	25,043
Stock-based compensation	(7,609)	(18,309)	(8,974)
Officers' compensation	4,024	2,612	3,133
Other	124	479	972
Change in valuation allowance	6,155	24,450	(13,919)
Income tax expense (benefit)	$ 335	$ (1,900)	$ 149

Income Taxes

12 Months Ended

Dec. 31, 2021

Income Tax Disclosure [Abstract]

Income Taxes

The income (loss) before provision for income taxes for the Company’s domestic and international operations was as follows (in thousands):


	Year Ended December 31,
	2021		2020		2019
U.S.	$	15,211	$	(36,667)	$	(24,888)
Foreign	690		385		284
Income (loss) before provision for income taxes	$	15,901	$	(36,282)	$	(24,604)

The components of income tax expense (benefit) were as follows (in thousands):


	Year Ended December 31,
	2021		2020		2019
Current:
Federal	$	—	$	—	$	—
State	174		75		86
Foreign	161		151		88
Total current tax expense	335		226		174
Deferred:
Federal	—		(1,760)		(21)
State	—		(366)		(4)
Foreign	—		—		—
Total deferred income tax benefit	—		(2,126)		(25)
Income tax expense (benefit)	$	335	$	(1,900)	$	149

The expense (benefit) for income taxes reconciles to the amount computed by applying the federal statutory rate to loss before taxes as follows (in thousands):


	Year Ended December 31,
	2021		2020		2019
Income tax expense (benefit) at federal statutory rate (1)	$	3,339	$	(7,619)	$	(5,167)
State income tax, net of federal benefit	(254)		(2,792)		(1,174)
Warrants revaluation	356		3,588		2,326
Research and development credits	(5,703)		(5,330)		(2,091)
Section 382 limitation	(97)		1,021		25,043
Stock-based compensation	(7,609)		(18,309)		(8,974)
Officers' compensation	4,024		2,612		3,133
Other	124		479		972
Change in valuation allowance	6,155		24,450		(13,919)
Income tax expense (benefit)	$	335	$	(1,900)	$	149

(1)For the years ended December 31, 2021, 2020 and 2019, the federal statutory tax rate was 21%.

Significant components of the Company’s net deferred income tax assets at December 31, 2021 and 2020 are shown below (in thousands). The Company assesses all available positive and negative evidence to estimate whether sufficient future taxable income will be generated to permit use of the existing deferred tax assets. A significant piece of objective negative evidence evaluated was the cumulative book loss incurred over the three-year period ended December 31, 2021. Such objective evidence limits the ability to consider other subjective evidence, such as projections for future growth. On the basis of this analysis, a valuation allowance of $146.4 million and $121.6 million at December 31, 2021 and 2020, respectively, has been recorded to offset the net deferred tax asset as realization of such asset is uncertain. The amount of the deferred tax asset considered realizable, however, could be adjusted if estimates of future taxable income during the carryforward period are increased, or if objective negative evidence in the form of cumulative losses is no longer present and additional weight is given to subjective evidence such as the Company’s projections for future growth.


	December 31,
	2021		2020
Deferred tax assets:
Net operating loss (NOL) carryforwards	$	78,961	$	86,898
Research and development tax credits carryforwards	16,761		11,261
Capitalized research and development expenses	5,135		6,840
Accrued compensation	28,970		24,038
Lease liabilities	8,012		6,112
Other	20,608		12,096
Total deferred tax assets	158,447		147,245
Deferred tax liabilities:
Convertible senior notes	—		(11,224)
Fixed assets	(3,847)		(7,675)
Other	(8,177)		(6,719)
Total deferred tax liabilities	(12,024)		(25,618)
Less valuation allowance	(146,423)		(121,627)
Net deferred tax assets	$	—	$	—

As of December 31, 2021, the Company had accumulated federal and state NOL carryforwards of approximately $301.2 million, and $291.0 million, respectively, Of the total federal net operating loss carryforwards, approximately $112.1 million were generated after January 1, 2018, and therefore do not expire. NOL generated after January 1, 2018, is subject to 80% limitation in accordance with the Tax Cuts and Jobs Act of 2017. The remaining federal net operating loss carryforwards of $189.1 million will begin to expire in 2026, and state tax loss carryforwards continue to expire in 2022, unless previously utilized. The remaining California NOL carryforwards of $171.8 million will begin expiring in 2028. The Company has no foreign tax loss carryforwards as of December 31, 2021.

The Company also has federal and California research credit carryforwards of approximately $12.9 million and $15.5 million, respectively, as of December 31, 2021. The federal research credit carryforwards will begin expiring in 2038, unless previously utilized. The California research credit will carry forward indefinitely.

Utilization of the Company's net operating loss and research credit carryforwards may be subject to a substantial annual limitation due to ownership change limitations provided by Section 382 of the Internal Revenue Code of 1986, as amended, and similar state provisions. The annual limitations may result in the expiration of net operating loss carryforwards before utilization. The Company has completed analyses through December 31, 2020 to determine whether its net operating losses and credits are likely to be limited by Section 382. Based on the 2018 study completed in 2019, the Company determined that an ownership change, as defined under Section 382, occurred in 2018 and the resulting limitation significantly reduced the Company’s ability to utilize its net operating loss and credit carryovers before they expire. As a result, in 2019 the Company reduced its deferred tax assets for the net operating loss and research credit carryforwards that were projected to expire unused with a corresponding offset to the valuation allowance recorded against such assets. Additionally, future ownership changes under Section 382 may also limit the Company's ability to fully utilize any remaining tax benefits.

The evaluation of uncertainty in a tax position is a two-step process. The first step involves recognition. The Company determines whether it is more likely than not that a tax position will be sustained upon tax examination, including resolution of any related appeals or litigation, based on only the technical merits of the position. The technical merits of a tax position are derived from both statutory and judicial authority (legislation and statutes, legislative intent, regulations, rulings, and case law) and their applicability to the facts and circumstances of the tax position. If a tax position does not meet the more-likely-than-not recognition threshold, the benefit of that position is not recognized in the financial statements. The second step is measurement. A tax position that meets the more-likely-than-not recognition threshold is measured to determine the amount of benefit to recognize in the financial statements. The tax position is measured as the largest amount of benefit that is greater than 50% likely of being realized upon ultimate resolution with a taxing authority.

The following table summarizes the activity related to the Company’s gross unrecognized tax benefits at the beginning and end of the years ended December 31, 2021, 2020 and 2019 (in thousands):


	Year Ended December 31,
	2021		2020		2019
Gross unrecognized tax benefits at the beginning of the year	10,107		$	6,580	$	8,824
Increases related to current year positions	3,482		2,234		1,076
Increases (decreases) related to prior year positions	—		1,293		(3,320)
Gross unrecognized tax benefits at the end of the year	$	13,589	$	10,107	$	6,580

As of December 31, 2021, the Company had $11.8 million of unrecognized tax benefits that, if recognized and realized would impact the effective tax rate, subject to the valuation allowance.

The Company’s practice is to recognize interest and penalties related to income tax matters in income tax expense. The Company had no accrual for interest and penalties on the Company’s consolidated balance sheets and has not recognized interest and penalties in the consolidated statements of operations for the years ended December 31, 2021 and 2020. The Company does not expect any significant increases or decreases, other than the potential reduction as a result of the Section 382 limitation, to its unrecognized tax benefits within the next 12 months.

The Company is subject to taxation in the United States and various other state jurisdictions and, starting with 2018, Canada. Prior to 2018, the losses were all domestic. The Company’s tax years from 2006 (inception) are subject to examination by the United States and state authorities due to the carry forward of unutilized NOLs and research and development credits.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 270
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI http://asc.fasb.org/topic&trid=2144680

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

+ Details